The report presents an in-depth assessment of the Longevity And Anti-senescence Therapy Market including enabling technologies, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future road map, value chain, ecosystem player profiles and strategies. The report also presents forecasts for Longevity And Anti-senescence Therapy investments from 2019 till 2025.The research study includes segmental analysis where important type, application, and regional segments are studied in quite some detail. It also includes market channel, customer analysis, manufacturing cost analysis, company profiles, market analysis by application, production, revenue, and price trend analysis by type, production and consumption analysis by region, and various other market studies.

The various contributors involved in the value chain of Longevity And Anti-senescence Therapy include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in the Longevity And Anti-senescence Therapy include: CohBar, TA Sciences, Unity Biotechnology, AgeX Therapeutics_Inc, PowerVision Inc.

Click the link to get a Sample Copy of the Report at :

https://www.marketinsightsreports.com/reports/08151417048/global-longevity-and-anti-senescence-therapy-market-size-status-and-forecast-2019-2025/inquiry?Mode=90

Longevity And Anti-senescence Therapy Marketon the basis ofby Type:Hemolytic Drug TherapyGene TherapyImmunotherapyOther Stem Cell Therapies

Longevity And Anti-senescence Therapy Breakdown Data by ApplicationHospitalMedical Service InstitutionDrug and Device Sales

Regional Analysis For Longevity And Anti-senescence Therapy Market:

North America(United States, Canada and Mexico)Europe(Germany, France, UK, Russia and Italy)Asia-Pacific(China, Japan, Korea, India and Southeast Asia)South America(Brazil, Argentina, Colombia etc.)Middle East and Africa(Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Additionally, the report enables a market player not only to plan but also execute lucrative Longevity And Anti-senescence Therapy business strategies based on growing market needs by emphasizing leading competitors strategic moves which include recent mergers, ventures, acquisitions, business expansion, product launches, branding, and promotional activities.

Furthermore, the report encompasses the key strategic developments of the market comprising new product launch, research & development, partnerships, acquisitions & mergers, collaborations & joint ventures agreements, and regional growth of main players in the market on the global and regional basis.

Global Longevity And Anti-senescence Therapy Industry 2019 Market Research Report is spread across 91 pages and provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

Inquire For Discount at:

https://www.marketinsightsreports.com/reports/08151417048/global-longevity-and-anti-senescence-therapy-market-size-status-and-forecast-2019-2025/discount?Mode=90

This report provides:

-Comprehensive assessment of all opportunities and risk in the Longevity And Anti-senescence Therapy market.

Longevity And Anti-senescence Therapy market recent innovations and major events.

-Detailed study of business strategies for growth of the Longevity And Anti-senescence Therapy market-leading players.

-Conclusive study about the growth plot of Longevity And Anti-senescence Therapy market for forthcoming years.

-In-depth understanding of Longevity And Anti-senescence Therapy market-particular drivers, constraints and major micro markets.

-Favorable impression inside vital technological and market latest trends striking the Longevity And Anti-senescence Therapy market.

Table of Contents:

Industry Overview of Longevity And Anti-senescence Therapy Market:

Market Segments:

The global Longevity And Anti-senescence Therapy market is segmented on the basis of type of product, application, and region. The analysts authoring the report provide a meticulous evaluation of all of the segments included in the report. The segments are studied keeping in view their market share, revenue, market growth rate, and other vital factors. The segmentation study equips interested parties to identify high-growth portions of the global Longevity And Anti-senescence Therapy market and understand how the leading segments could grow during the forecast period.

To Buy Report:

https://www.marketinsightsreports.com/report/purchase/08151417048?mode=su&mode=90

About Us:

MarketInsightsReportsprovides syndicated market research reports to industries, organizations or even individuals with an aim of helping them in their decision making process.MarketInsightsReportsprovides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

sales@marketinsightsreports.com | irfan@marketinsightsreports.com

Read the original here:
Longevity And Anti-senescence Therapy Market Research on Trend, Demand and Precise Outlook 2019-2025 - The Ukiah Post

Recommendation and review posted by Bethany Smith

Gene Therapy Market look into report is a in-depth analysis of current situation of the market, which covers a few market dynamics. A isolate area with Gene Therapy industry key players is incorporated into the report, which gives a far reaching investigation of sales and revenue, value, cost, gross, product picture, details, organization profile, and contact data. The Market Report additionally gives a diagnostic appraisal of the prime difficulties looked by Gene Therapy Market at present and in the coming years, which helps Market members in understanding the issues they may face while working in this Market over a more extended timeframe.

Market Segmentation: Key Players

Avalanche BioAdvantageneDimension TherapeuticsBluebird BioSangamoCelladonVical Inc.Spark Therapeutics

Click Here For Complete Sample Copy:https://www.globalmarketers.biz/report/life-sciences/global-gene-therapy-market-report-2019,-competitive-landscape,-trends-and-opportunities/134347#request_sample

The report gives the concise examination report of the Gene Therapy Market showcase around the United States. The Gene Therapy think about contributes tasteful answer for the client. The examination think about incorporates investigation, Gene Therapy market forecast and income from 2019 to 2026. The Gene Therapy report unveils the near outcome between various players spread in the United States. It likewise gives the different kinds of sections of the Gene Therapy market seeing to the item, for example, type, Regions/Countries, application and players. Current and refreshed Gene Therapy trends likewise included to the report.

This Gene Therapy report analyzes the global market by the following segments:

Global Gene Therapy Market Analysis By Product Types:

In VivoEx Vivo

Global Gene Therapy Market Analysis By Product Applications:

Cardiovascular DiseasesInfectious DiseasesMonogenic DiseasesCancer DiseasesOthers

Inquiry Here For Detail Report @ https://www.globalmarketers.biz/report/life-sciences/global-gene-therapy-market-report-2019,-competitive-landscape,-trends-and-opportunities/134347#inquiry_before_buying

Gene Therapy Industry fragment based on research regions:

The fundamental regions analyzed in this report include North America, Europe, Asia-Pacific, Middle East& Africa and South America. The growth rate and production value are analyzed for these regions. Further, the above regions are bifurcated to provide country-level Gene Therapy industry statistics for the below countries.

North America region covers the United States, Canada and the rest of the countries

Europe regions cover the Gene Therapy market statistics for Germany, The UK, France, Netherlands, Italy, Spain and rest of the countries

Asia-Pacific region covers the industry analysis for China, Japan, Korea, India, and rest

The Middle East and African Gene Therapy market caters to South Africa, Israel, UAE and rest

South America covers countries like Brazil, Colombia, Argentina and rest

The global Gene Therapy research report plots a part of the key players existing in the Gene Therapy Market, close by point to point investigation. The report delineates each one of the concentrations concerning how showcase players are going for the creating market part of various locales. Recent strategic association, organization, assention, mergers, and acquisitions occurring in the global Gene Therapy showcase are being fused. The basic progress included towards the examination of entire market regard, in view of end-customer Gene Therapy advertise and land areas.

Research Report Covers

Gene Therapy Market Overview. Global Gene Therapy Market Competition by Manufacturer.

Global Gene Therapy Capacity, Production, Revenue(value) by region(2014-2019).

Global Gene Therapy Supply(Production), Consumption, Export, Import By Region(2014-2019)

Global Gene Therapy Capacity, Production, Revenue(value), Price Trend by Type.

Global Gene Therapy Market Analysis By Application.

Global Gene Therapy Manufacturers profiles/Analysis

Global Gene Therapy Manufacturing Cost Analysis

Industrial chain, sourcing strategy and downstream buyers.

Marketing stratergy analysis, Distributors/Traders.

Global Gene Therapy Market Forecast Analysis(2019-2026).

Research Finding and Conclusions.

Appendix.

Explore Full Report With Detailed TOC Here @ https://www.globalmarketers.biz/report/life-sciences/global-gene-therapy-market-report-2019,-competitive-landscape,-trends-and-opportunities/134347#table_of_contents

Read more:
Global Gene Therapy Market- Industry Growth, Trends, New Tech Developments, Revenue Predicted to 2026 - Space Market Research

Recommendation and review posted by Bethany Smith

BERKELEY, Calif., Oct. 1, 2019 /PRNewswire/ --Today, the U.S. Patent and Trademark Office (USPTO) granted a new CRISPR-Cas9 patent to the University of California (UC), University of Vienna, and Dr. Emmanuelle Charpentier covering new methods of the gene-editing technology in prokaryotic cells. The new patent (U.S. Patent No. 10,428,352) covers methods of targeting and binding or methods of cleaving a target DNA in a prokaryotic cell using Cas9 protein and single molecule DNA targeting RNAs. This patent also specifically covers these methods in bacterial cells.

This is the fifth consecutive week that the USPTO has awarded a CRISPR-Cas9 patent to UC, which has immensely increased the compositions and methods covered in the portfolio. The university's total portfolio to-date includes 16 patents, marking the largest CRISPR-Cas9 patent portfolio in the country, and will rise to 18 in the coming weeks, once other applications that the USPTO has allowed are issued as patents. The extensive portfolio covers compositions and methods for the CRISPR-Cas9 gene-editing technology, including targeting and editing genes and modulating transcription in any setting, such as within plant, animal, and human cells.

"The continuous issuance of CRISPR-Cas9 patents to UC adds significant new compositions and methods to our burgeoning portfolio that has quickly become the widest-ranging for the technology," said Eldora L. Ellison, Ph.D., lead patent strategist on CRISPR-Cas9 matters for UC and a Director at Sterne, Kessler, Goldstein & Fox. "We are pleased by the USPTO's ongoing recognition of the Doudna-Charpentier team's leadership related to CRISPR-Cas9."

The Doudna-Charpentier team that invented the CRISPR-Cas9 DNA-targeting technology included Jennifer Doudna and Martin Jinek at the University of California, Berkeley; Emmanuelle Charpentier (then of Umea University); and Krzysztof Chylinski at the University of Vienna. The methods covered by today's patent, as well as the other compositions and methods claimed in UC's previously issued patents and those set to issue, were included among the CRISPR-Cas9 gene editing technology work disclosed first by the Doudna-Charpentier team in its May 25, 2012 priority patent application.

Additional CRISPR-Cas9 patents in this team's portfolio include 10,000,772; 10,113,167; 10,227,611; 10,266,850; 10,301,651; 10,308,961; 10,337,029; 10,351,878; 10,358,658; 10,358,659; 10,385,360; 10,400,253; 10,407,697; 10,415,061; and 10,421,980. These patents are not a part of the PTAB's recently declared interference between 14 UC patent applications and multiple previously issued Broad Institute patents and one application, which jeopardizes essentially all of the Broad's CRISPR patents involving eukaryotic cells.

International patent offices have also recognized the pioneering innovations of the Doudna-Charpentier team, in addition to the 16 patents granted in the U.S. so far. The European Patent Office (representing more than 30 countries), as well as patent offices in the United Kingdom, China, Japan, Australia, New Zealand, Mexico, and other countries, have issued patents for the use of CRISPR-Cas9 gene editing in all types of cells.

University of California has a long-standing commitment to develop and apply its patented technologies, including CRISPR-Cas9, for the betterment of humankind. Consistent with its open-licensing policies, UC allows nonprofit institutions, including academic institutions, to use the technology for non-commercial educational and research purposes.

In the case of CRISPR-Cas9, UC has also encouraged widespread commercialization of the technology through its exclusive license with Caribou Biosciences, Inc. of Berkeley, California. Caribou has sublicensed this patent family to numerous companies worldwide, including Intellia Therapeutics, Inc. for certain human therapeutic applications. Additionally, Dr. Charpentier has licensed the technology to CRISPR Therapeutics AG and ERS Genomics Limited.

SOURCE University of California Office of the President

Original post:
University of California expands US CRISPR-Cas9 patent portfolio with issuance of new patent - PRNewswire

Recommendation and review posted by Bethany Smith

A scientific studypublished this past spring came with damning implications for Chinese scientist He Jiankui, who created the worlds first gene-edited babies: People with the rare genetic variants that Hetried to engineer into embryos, the study asserted, had an increaseddeath rate.

On [September 27], the papers senior author said his study was wrong.

The study centers around the effects of a variant of the gene known as CCR5, called 32, which is best known for protecting against infection with HIV, the virus that causes AIDS.

[Author Rasmus] Nielsen told STAT that the error stemmed from the specific single nucleotide polymorphism, or genetic marker, that he and [collaborator Xinzhu] Wei looked at. In the U.K. Biobank data, the marker they chose to work with had systematic errors related to genotype calling at that site in the DNA; thats the process by which the genotype is determined for each individual in the sample at each site.

The way the genotypes were being called caused certain genotypes to show up less frequently than they should have, Nielsen said, apparently generating the erroneous signal around increased mortality.

Read full, original post: Major error undermines study suggesting change introduced in the CRISPR babies experiment shortens lives

The rest is here:
Researcher backtracks on study suggesting He Jiankui's controversial CRISPR babies will have shorter lifespans - Genetic Literacy Project

Recommendation and review posted by Bethany Smith

XconomyBoston

A number of gene-editing companies have joined the public markets in recent years. Beam Therapeutics, which is developing a CRISPR-based technology intended to offer even more precise genomic edits, aims to become the latest one.

Cambridge, MA-based Beam filed its IPO paperwork with securities regulators late Friday. The company set a preliminary $100 million target for the offering. It has applied for a Nasdaq listing under the stock symbol BEAM.

CRISPR-Cas9 gene editing cuts the genome at specific locations in order to remove or add a piece of DNA. But Beam contends theres room to make CRISPR editing even more precise. If you picture the double helix structure of DNA as a ladder, each rung is made up of a base pair, which consists of two bases. Many genomic mutations occur in a single base. Beams technology, called base editing, is being developed to target these single base errors, which are called point mutations.

If existing gene editing approaches are scissors for the genome, our base editors are pencils, erasing and rewriting one letter in the gene, Beam says in its IPO prospectus.

Beam faces plenty of competition in the gene editing space. Other companies using CRISPR-Cas9 technology to develop new therapies include Caribou Biosciences, Editas Medicine (NASDAQ: EDIT), CRISPR Therapeutics (NASDAQ: CRSP), and Intellia Therapeutics (NASDAQ: NTLA). But the ability to edit point mutations could make the Beam technology applicable to a broader range of genetic diseases. The company says point mutations represent 58 percent of all known genetic errors associated with disease.

Beam was founded in 2017. Until now, Beam has kept quiet about which diseases it aims to treat. The companys filing lists 12 programs, including the blood disorders beta thalassemia and sickle cell disease, and the blood cancers acute lymphoblastic leukemia and acute myeloid leukemia. The pipeline also includes potential treatments for liver diseases, as well as disorders of the eye and the central nervous system.

All of Beams programs are preclinical. For most of them, the company says it has demonstrated therapeutically relevant base editing of cells in the lab. Next year, Beam aims to show that it can base edit genes in animals, tests that are slated for next year. If all goes well, Beam says it could start filing for clearance to begin human testing for multiple programs in 2021.

Beam has raised more than $223 million; its most recent financing was a $135 million Series B round in April. The company still has plenty of money in its coffers: As of June 30, Beam reported $126.8 million in cash holdings. The company says it will use the IPO proceeds to continue research and development of its base editing programs. According to the IPO filing, ARCH Venture partners is Beams largest shareholder with a 23 percent stake followed by F-Prime Capital Partners Healthcare Fund, which owns 19.4 percent of the company.

Heres more on the origins of Beam, which is based on research from Harvard University, the Broad Institute, and Massachusetts General Hospital.

Photo by Flickr user marco.savia a Creative Commons license

Frank Vinluan is editor of Xconomy Raleigh-Durham, based in Research Triangle Park. You can reach him at fvinluan [at] xconomy.com

Go here to see the original:
Beam Therapeutics Preps IPO and Sheds Light on Its Gene-Editing Drugs - Xconomy

Recommendation and review posted by Bethany Smith

CRISPR Therapeutics AG (CRSP):

If you are considering getting into the day trading or penny stock market, its a legitimate and profitable method for making a living. Every good investor knows that in order to make money on any investment, you must first understand all aspects of it, so lets look at daily change, stock price movement in some particular time frame, volatility update, performance indicators and technical analysis and analyst rating. Picking a stock is very difficult job. There are many factors to consider before choosing a right stock to invest in it. If picking stock was easy, everyone would be rich right? This piece of financial article provides a short snap of CRISPR Therapeutics AG (CRSP) regarding Monday trading session and presents some other indicators that can help you to support yours research about CRISPR Therapeutics AG (CRSP).

CRISPR Therapeutics AG (CRSP) stock Trading Summary:

CRISPR Therapeutics AG (CRSP) stock changed position at -3.23% to closing price of $40.99 in recent trading session. The last closing price represents the price at which the last trade occurred. The last price is also the price on which most charts are based; the chart updates with each change of the last price. The stock registered Monday volume of 435486 shares. Daily volume is the number of shares that are traded during one trading day. High volume is an indication that a stock is actively traded, and low volume is an indication that a stock is less actively traded. Some stocks tend always to have high volume, as they are popular among day traders and investors alike. Other stocks tend always to have low volume, and arent of particular interest to short-term traders. The stock average trading capacity stands with 459.2K shares and relative volume is now at 0.9.

CRISPR Therapeutics AG (CRSP) Stock Price Movement in past 50 Days period and 52-Week period

CRISPR Therapeutics AG (CRSP) stock demonstrated 84.47% move opposition to 12-month low and unveiled a move of -23.95% versus to 12-month high. The recent trading activity has given its price a change of -23.95% to its 50 Day High and -0.02% move versus to its 50 Day Low. Prices of commodities, securities and stocks fluctuate frequently, recording highest and lowest figures at different points of time in the market. A figure recorded as the highest/lowest price of the security, bond or stock over the period of past 52 weeks is generally referred to as its 52-week high/ low. It is an important parameter for investors (as they compare the current trading price of the stocks and bonds to the highest/lowest prices they have reached in the past 52 weeks) in making investment decisions. It also plays an important role in determination of the predicted future prices of the stock.

CRISPR Therapeutics AG (CRSP) Stock Past Performance

CRISPR Therapeutics AG (CRSP) stock revealed -12.30% return for the recent month and disclosed -14.09% return in 3-month period. The stock grabbed 15.63% return over last 6-months and -11.74% return in yearly time period. To measure stock performance since start of the year, it resulted a change of 43.47%. Past performance shows you the funds track record, but do remember that past performance is not an indication of future performance. Read the historical performance of the stock critically and make sure to take into account both long- and short-term performance. Past performance is just one piece of the puzzle when evaluating investments. Understanding how performance fits in with your overall investing strategy and what else should be considered can keep you from developing tunnel vision.

Volatility in Focus:

The stock unfolded volatility at 5.66% during a week and it has been swapped around 4.43% over a month. Volatility is a rate at which the price of a security increases or decreases for a given set of returns. Volatility is measured by calculating the standard deviation of the annualized returns over a given period of time. It shows the range to which the price of a security may increase or decrease. Volatility measures the risk of a security. It is used in option pricing formula to gauge the fluctuations in the returns of the underlying assets. Volatility indicates the pricing behavior of the security and helps estimate the fluctuations that may happen in a short period of time. If the prices of a security fluctuate rapidly in a short time span, it is termed to have high volatility. If the prices of a security fluctuate slowly in a longer time span, it is termed to have low volatility.

The average true range is a volatility indicator. This stocks Average True Range (ATR) is currently standing at 2.04.

Overbought and Oversold levels

The stock has RSI reading of 29.88. RSI gives an indication of the impending reversals or reaction in price of a security. RSI moves in the range of 0 and 100. So an RSI of 0 means that the stock price has fallen in all of the 14 trading days. Similarly, an RSI of 100 means that the stock price has risen in all of the 14 trading days. In technical analysis, an RSI of above 70 is considered an overbought area while an RSI of less than 30 is considered as an oversold area. RSI can be used as a leading indicator as it normally tops and bottoms ahead of the market, thereby indicating an imminent correction in the price of a security. It is pertinent to note that the levels of 70 and 30 needs to be adjusted according to the inherent volatility of the security in question.

Analyst Watch: Analysts have assigned their consensus opinion on this stock with rating of 2.3 on scale of 1 to 5. 1 or 2 =>Buy view 4 or 5 => Sell opinion. 3 =>Hold. Analysts recommendations are the fountainhead of equity research reports and should be used in tangent with proprietary research and investment methodologies in order to make investment decisions.

Christopher Jones

Category Finance

Christopher Jones says that his huge experience in 5 years, gives him priority among others. He worked for different national and international companies. He has unique insights into the investments for oil and gas field. He likes to share his predictions and analysis with readers. He still creates profitable equity portfolios for his clients.

Christopher has worked as an auditor for many years but is currently working as a business journalist so that he can work remotely and travel with his wife while she works as a travel nurse for several years. Christopher specializes in stock, gas and oil investments, dividends. He is a well-known person in Finance world.

Address: 1646 Lone Mountain Road, O Brien, OR 97534 USA

Email: [emailprotected]

Zip code: 97534

Contact # 541-479-1890

Go here to read the rest:
Stock In Active Zone:: CRISPR Therapeutics AG (CRSP) - WEB NEWS OBSERVER

Recommendation and review posted by Bethany Smith

Franoise BaylisHarvard University Press2019297 pp.Purchase this item now

With Altered Inheritance, bioethicist Franoise Baylis has authored a vivid call to action that aims to bridge the divides between theory, science, politics, and practice in response to increased public awareness and scientific applications of CRISPR/Cas9 technology. She achieves her aim in this timely and important book.

Baylis calls for broad societal consensus and shared responsibility to guide heritable gene editing toward the common good, which she defines as that which is essential for survival and well-being, to which the market, property, and liberty are subordinate. Her call demands an urgent response, as she notes that humanity sits precipitously on the verge of either a new beginning or the beginning of the end.

A prologue and epilogue bookend the 10 chapters that comprise Altered Inheritance. The back matter includes an index to make the material accessible for scientifically curious general readers, scientists interested in the ethical dimensions of gene editing, and bioethicists seeking an innovative framework to direct theorizing and practice in the era of CRISPR.

Baylis seamlessly threads definitional and conceptual content into the first three chapters, which include critical information for readers who do not have a strong background in the terms and technology of gene editing. The first chapter analyzes Huntingtons disease as a case study for targeting a single gene. Chapter two distinguishes somatic from germline editingthe former being an edit that affects an individual, the latter being one that will be passed on to the individuals descendants. Heritable gene editing is the main focus of the book.

In chapter three, Baylis constructs a brief history of gene editing, using the case of designer babies as a central example. (Incidentally, the term designer baby was first coined to capture marketing-influenced, brand-heavy consumer behavior and only later came to be applied to gene editing.) She concludes this chapter with an expert philosophical discussion that shows that the demarcation between health-related editing and nonhealth-related editing is not as clear as our intuitions may lead us to believe. Cognitive enhancement through traditional means, including reading and education, may only be a difference of degree, not of kind, from gene editing that selects for particular cognitive traits.

Baylis continues this important discussion into chapter four, in which she argues that all medical treatments are a form of enhancementimproving or returning an aberrant gene to its normal status. However, not all enhancements, she argues, are treatments. If one accepts this premise, the pertinent ethical question is not whether treatments should be allowed and nonmedical enhancements prohibited but whether heritable gene editing of any stripe may be structured to promote equality, access, and fairness.

In chapter six, Baylis continues her discussion of the possible harms and benefits of germline editing through the lens of potential moral wrongs. She worries, for example, about the opportunity costs that could occur when science and technology funding is diverted toward gene editing research, the benefits of which may then only be accessible to those with economic means. Baylis encourages the public and scientists alike to ask first, how gene editing science will improve the human condition, and second, what kind of world they want to live in.

Baylis introduces the idea of impact ethics in chapter nine. Following a heuristic articulated in feminist ethics, in which one sets aside a traditional notion of individual autonomy, impact ethics advances a relational understanding of autonomy, viewing people as interdependent. Here, Baylis also resists the notion that experts have privileged access to the truth.

Decisions about the use of genetic technology are too important to be left to scientists, writes Baylis in chapter 10. This provocative claim is not intended as a negative account of scientists involvement in the gene editing debate nor as a prohibition on their ongoing work. Rather, it is meant as a call for bidirectional engagement between scientists and the public. Public empowerment in these integral policy discussions is something all of us may and should participate in.

Commitments to justice, responsibility, accountability, and consensus-building are features of a socially just science and bioethics. Toward this end, Altered Inheritance is a foundational tool in the path ahead.

The reviewer is a philosopher of science and freelance writer based in Indianapolis, IN, USA.

Read the original here:
A new book offers an introduction to the ethical dimensions of germline gene editing - Science Magazine

Recommendation and review posted by Bethany Smith

The race to build the cutting edge banana is on. The Colombian government affirmed a month ago that a banana-killing organism has attacked the Americas the wellspring of a great part of the worlds banana supply. The intrusion has given new earnestness to endeavors to make organic product that can withstand the scourge.

Researchers are utilizing a blend of ways to deal with spare the banana. A group in Australia has embedded a quality from wild bananas into the top business assortment known as the Cavendish and are right now testing these adjusted bananas in field preliminaries. Scientists are additionally going to the amazing, exact quality altering device CRISPR to support the Cavendishs flexibility against the growth, known as Fusarium wither tropical race 4 (TR4).

Reproducing TR4 opposition into the Cavendish utilizing ordinary techniques is absurd on the grounds that the assortment is sterile and proliferated by cloning. So the best way to spare the Cavendish might be to change its genome, says Randy Ploetz, a plant pathologist at the University of Florida in Homestead. The assortment represents 99% of worldwide banana shipments.

James Dale, a biotechnologist at Queensland University of Technology in Brisbane, Australia, began getting enquiries about his hereditarily altered (GM) bananas in July, as the primary gossipy tidbits surfaced that TR4 had arrived at Colombia. At that point Colombia pronounced a national crisis, Dale says, and now the measure of intrigue is through the rooftop.

This isnt the first occasion when that a business banana assortment has confronted eradication. In the main portion of the 1900s, another strain of the Fusarium parasite got TR1 almost cleared out the times head honcho, the Gros Michel. Be that as it may, ranchers had reinforcement in the Cavendish, which was impervious to TR1, intense enough to withstand taking care of during export and had an extensively adequate surface and taste. By the 1960s, enormous banana cultivators, for example, Chiquita, presently situated in Fort Lauderdale, Florida, were changing to the Cavendish.

Theres no simple elective this time. Rodomiro Ortiz, a plant geneticist at the Swedish University of Agricultural Sciences in Alnarp, says that no normally happening banana species has the characteristics that have made the Cavendish so well-known and the capacity to oppose TR4.

The U.S. Patent and Trademark Office (USPTO) has granted another patent to the University of California (UC), University of Vienna, and Dr. Emmanuelle Charpentier covering techniques for delivering a hereditarily altered cell through the presentation of the Cas9 protein, or

As the world restlessly screens the episode of Ebola in Democratic Republic of the Congo, wellbeing authorities note that a measles flare-up announced a month ago in the nation has killed more individualsfor the most part kidsand quicker. Since January

Among the numerous worldwide issues today, the battle against antimicrobial opposition (AMR) urgently needs a comparable leap forward responsibility. For promoters, AMR's appearance on the G20's plan a year ago, at the gathering's summit in Hangzhou, China, spoke to a

Link:
CRISPR is the only hope against deadly funguses - BPhrm Dv

Recommendation and review posted by Bethany Smith

Formula One legend Michael Schumacher suffered life-changing head injuries in a skiing accident in 2013 and has since been receiving care at his home in Switzerland. It is believed the record-breaking racing driver cannot walk or stand and may have trouble communicating according to former Ferrari manager Jean Todt. So far Mr Schumachers treatment has been kept private, and nothing has been confirmed officially, however now the racing legend is under the care of world-renowned cardiac surgeon Philippe Menasch.

Mr Menasch is described as a pioneer in cell surgery at his hospital, Georges-Pompidou, in Paris.

According to the NHS: Stem cells are special cells produced by bone marrow (a spongy tissue found in the centre of some bones) that can turn into different types of blood cells.

The cells have been used since the 1980s to grow skin grafts for patients who have suffered life-threatening burns.

Read More:Michael Schumacher health update: Where is Michael Schumacher now?

They are also used in cancer treatments for cancers of the blood, and most recently have been used in repairing damage to the cornea - surface of the eye.

A lot about stem cells is still being discovered, with clinical trials taking place for illnesses and conditions like MS and macular degeneration, heart disease and spinal cord injuries.

The special cells are also being used in neurodegenerative diseases like Parkinsons and Alzheimers and traumatic brain injuries like Mr Schumachers.

In an interview online, Mr Menasch explained stem cell treatment for cardiac conditions is only touching the surface.

Read More:Michael Schumacher could be able to cry and move his thumbs'

He said: Nobody really knows how stem cells are working.

They do not permanently transplant into the myocardium, the muscular tissue of the heart after a couple of days or weeks they just disappear.

Mr Schumacher received stem cell therapy in September in Paris, however, not much information has surfaced about the procedure.

MrMenasch spoke to Italian newspaper La Repubblica and said: There was an explosion in the attention our department received but the situation has already normalised.

Local media dubbed the procedure experimental however MrMenasch denied this saying: everyone is looking for me but I have not used experimental cures.

I do not perform miracles. My team and I are not doing an experiment, an abominable term that is not in line with a serious medical view.

Michael Schumacher is motor racings most successful driver, with a record 91 Grand Prix wins.

He won his first titles with Benetton in 1994 and 1995 followed by five in a row with Ferrari between 2000-2004.

More here:
Michael Schumacher health latest: What is stem cell therapy and how will it help Schumi? - Express.co.uk

Recommendation and review posted by Bethany Smith

The global stem cell therapy market growth has been primarily attributed to the major drivers in this market such as the increasing prevalence of chronic diseases, rising number of clinical trials for cell-based therapy, steady investment, and consolidation in the regenerative medicine market, and favorable regulatory environment.

Get free pdf sample : https://www.marketindustryreports.com/pdf/32

Key Players in the Stem Cell Therapy Market are:

Market Definition: Stem Cell Therapy Market

Stem cells are human cells that have the ability to develop into various cell types such as muscle cells, brain cells they also have the unique ability to repair damaged tissue. Stem cells are divided into two major categories namely: embryonic stem cells and adult stem cells. The embryonic stem cell that is being used to conduct research today came from unused embryos resulting from an in vitro fertilization process which were later donated to science. These embryonic stem cells are pluripotent this basically means that they can turn into more than one type of cell. There are two types of adult stem cells- one of the type comes from fully developed tissues, such as the brain, the skin, and even bone marrow. The second type is induced pluripotent stem cells. These are adult stem cells that have been manipulated in a laboratory to take on characteristic of embryonic stem cells which enables them to turn into more than one type of cell.

The worldwide Stem Cell Therapy Market report give point by point data about the Stem Cell Therapy Market with a fitting examination of a few parameters and patterns impacting its advancement at a worldwide premise.

Scope of the Market :

The stem cell therapy market research provides a holistic view of the stem cell therapy market in terms of various factors influencing it, including regulatory reforms, and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products allied with the therapeutic application of stem cells. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, the growth potential of each underlying sub-segment, and company, as well as other vital information with respect to global stem cell therapy market.

Market Segmentation

Market drivers: Stem Cell Therapy Market

Market Restraints: Stem Cell Therapy Market

Key Developments: CRISPR Technology Market

Stem cell therapy is accelerating at a huge growth circle that promises a potential for diversified career opportunities.

Get exclusive discount on report : https://www.marketindustryreports.com/discount/32

Table of Contents

INTRODUCTION

RESEARCH METHODOLOGY

In light of the examination of affecting development and constraining parameters, the exact information showing the future development pattern of the market can be gotten, which is altogether clarified in the Stem Cell Therapy Market research report. The data with respect to the moving toward circumstances that can help the market capitalization is additionally incorporated into the report. The report likewise involves fundamental data, for example, yearly income age, advertise esteem, use, yearly deals, and other significant measurable information, with respect to the key market contenders which incorporate a few associations, firms, item makers, sellers, and wholesalers.

Get exclusive discount on report : https://www.marketindustryreports.com/discount/32

Read More About Report Click Here:

About Us

Market Industry Reports is a global leader in market measurement and advisory services. It is 100% subsidiary of Maniks Systems Pvt Ltd. The firm has always been at the forefront of innovation to address the worldwide industry trends and opportunities.

Contact Us-

2nd Floor, Manikchand Ikon,

B-Wing, Dhole Patil Road,

Sangamwadi, Pune 411 001

Email: [emailprotected]Phone: +1 347 767 5477 ( US )+ 91 8956 767 535 ( IN )Website: https://www.marketindustryreports.com/Follow Us- LinkedIn | Twitter | Facebook

See the rest here:
Global Stem Cell Therapy Market Report, 2019-2030 : Focus on Treatment Type, Cell Source, Indication and Competitive Landscape - Space Market Research

Recommendation and review posted by Bethany Smith

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), will today announce positive results from a single-arm cohort of the Phase II/III Blood First Assay Screening Trial (BFAST), the first prospective study to use only blood-based next generation sequencing (NGS) to detect specific fusions with the aim of selecting treatment for people with advanced non-small cell lung cancer (NSCLC), without the need for tissue biopsy. Results from the anaplastic lymphoma kinase (ALK) cohort will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress on Monday, September 30 from 9:15 9:30 a.m. CEST (Abstract LBA81 PR) and were also part of the official ESMO press program.

Obtaining tumor tissue for biomarker testing can be a challenge in many people with cancer and, as a result, some may not receive optimal treatment for their disease, said Sandra Horning, M.D., chief medical officer and head of Global Product Development. BFAST is the first trial to show that by using a blood-based next-generation diagnostic, it is possible to identify the ALK mutation in people with non-small cell lung cancer using a blood draw alone, which means that more people could potentially benefit from Alecensa.

Foundation Medicine is pleased to partner with Roche on this study, a first-of-its-kind, pivotal trial that directly demonstrates the clinical utility of using our comprehensive blood-based assay, FoundationOne Liquid, to detect specific fusions and match NSCLC patients with first-line treatment, said Brian Alexander, M.D., chief medical officer of Foundation Medicine. Validated and comprehensive liquid biopsy tests are critical to help physicians find the best possible treatment approach for patients with advanced cancer and for whom tissue testing isnt feasible. Identifying ALK fusions can be particularly challenging and these data demonstrate that FoundationOne Liquid can accurately predict which patients can respond to therapy.

The BFAST study used FoundationOne Liquid, Foundation Medicines comprehensive liquid biopsy test, which detects the four main classes of genomic alterations, microsatellite instability (MSI) and select fusions including ALK in circulating tumor DNA (ctDNA) from a blood draw. These data demonstrate that the FoundationOne Liquid assay can help to test and identify a broader population of people with advanced NSCLC who may benefit from Alecensa, for whom current diagnostic tests are not suitable, such as for those who cannot provide tissue samples due to insufficient or absent tumor tissue, or where tissue diagnostics are not available, and validate the clinical utility of blood-based NGS as an additional method to inform clinical decision-making in ALK-positive NSCLC.

In the study, 87.4% (95% CI: 78.5-93.5) of people with advanced NSCLC who were identified by the FoundationOne Liquid biopsy assay to have ALK fusions had a confirmed response to treatment with Alecensa (overall response rate; ORR) as measured by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). This is consistent with the ORR for Alecensa observed in the pivotal Phase III ALEX trial, which identified people using tissue-based testing. When measured using an Independent Review Facility per RECIST v1.1, the confirmed ORR was numerically higher at 92.0% (95% CI: 84.1-96.7). Median progression free-survival (PFS) and duration of response (DoR) were not reached after a median follow-up of 12.6 months. The safety profile of Alecensa was consistent with prior clinical trials and post-marketing experience, with no new safety signals observed.

About the BFAST study

BFAST (Blood First Assay Screening Trial) (NCT03178552) is a Phase II/III global, multi-center, open-label, multi-cohort study evaluating the safety and efficacy of targeted therapies or immunotherapies as single agents or in combination in people with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or be tumor mutational burden (TMB)-positive as identified by blood-based NGS ctDNA assays. The Alecensa ALK-positive cohort is the first to readout, with other cohorts due to follow. The primary endpoint for the Alecensa ALK-positive cohort of the BFAST study is confirmed investigator (INV)-assessed ORR. Secondary endpoints include: independent review facility (IRF)-assessed ORR, DoR (INV and IRF), PFS (INV and IRF), overall survival (OS) and safety.

About lung cancer

According to the American Cancer Society, it is estimated that more than 228,000 Americans will be diagnosed with lung cancer in 2019, and NSCLC accounts for 80-85% of all lung cancers. It is estimated that approximately 60% of lung cancer diagnoses in the United States are made when the disease is in the advanced stages.

About Alecensa (alectinib)

Alecensa is a kinase inhibitor approved for the treatment of people with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

Alecensa U.S. Indication

Alecensa is a kinase inhibitor approved for the treatment of people with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

Important Safety Information

Everyone reacts differently to treatment with Alecensa. Its important to know the most serious and most common side effects with Alecensa.

A doctor may lower the dose or stop treatment with Alecensa if any serious side effects occur. Patients taking Alecensa should contact their doctor right away if they have any of the following side effects.

Alecensa may cause serious side effects, including:

Liver problems (hepatotoxicity). Alecensa may cause liver injury. A doctor will do blood tests at least every 2 weeks for the first 3 months and as needed during treatment with Alecensa. Patients taking Alecensa should tell their doctor right away if they experience any of the following signs and symptoms:

Lung problems. Alecensa may cause severe or life-threatening swelling (inflammation) of the lungs during treatment. Symptoms may be similar to those symptoms from lung cancer. Patients taking Alecensa should tell their doctor right away if they have any new or worsening symptoms, including:

Kidney problems. Alecensa may cause severe or life-threatening kidney problems. Tell your healthcare provider right away if you have a change in the amount or color of your urine, or if you get new or worsening swelling in your legs or feet.

Slow heartbeat (bradycardia). Alecensa may cause very slow heartbeats that can be severe. A doctor will check a patients heart rate and blood pressure during treatment with Alecensa. Patients taking Alecensa should tell their doctor right away if they feel dizzy, lightheaded, or faint during treatment with Alecensa. Patients taking Alecensa should tell their doctor if they take any heart or blood pressure medicines.

Muscle pain, tenderness, and weakness (myalgia). Muscle problems are common with Alecensa and can be severe. A doctor will do blood tests at least every 2 weeks for the first month and as needed during treatment with Alecensa. Patients taking Alecensa should tell their doctor right away if they have any new or worsening signs and symptoms of muscle problems, including unexplained muscle pain or muscle pain that does not go away, tenderness, or weakness.

Before taking Alecensa, patients should tell their doctor about all medical conditions, including if they:

Patients taking Alecensa should tell their doctor about all the medicines they take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements.

Patients taking Alecensa should avoid spending time in the sunlight during treatment with Alecensa and for seven days after the final dose of Alecensa. Patients taking Alecensa may burn more easily and get severe sunburns. Patients taking Alecensa should use sunscreen and lip balm with a SPF 50 or greater to help protect against sunburn.

The most common side effects of Alecensa include:

These are not all of the possible side effects of Alecensa. For more information, patients should ask their doctor or pharmacist. Patients should call their doctor for medical advice about side effects.

Report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch. Patients and caregivers may also report side effects to Genentech at (888) 835-2555.

Please see additional Important Safety Information in full Prescribing Information, including Patient Information.

About Foundation Medicine

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company, a member of the Roche Group, offers a full suite of comprehensive genomic profiling tests to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicines molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer.

For more information, please visit http://www.foundationmedicine.com or follow Foundation Medicine on Twitter (@FoundationMedicineATCG).

About Genentech in Lung Cancer

Lung cancer is a major area of focus and investment for Genentech, and we are committed to developing new approaches, medicines and tests that can help people with this deadly disease. Our goal is to provide an effective treatment option for every person diagnosed with lung cancer. We currently have five approved medicines to treat certain kinds of lung cancer and more than 10 medicines being developed to target the most common genetic drivers of lung cancer or to boost the immune system to combat the disease.

About Genentech

Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.

Excerpt from:
Genentech to Present Results of First Prospective Trial Using Blood-based Next Generation Sequencing Which Successfully Identifies People for...

Recommendation and review posted by Bethany Smith

By Brandon Showalter, CP Reporter | Thursday, September 26, 2019 Lupron, puberty blocker and prostate cancer drug.

Drugs that are being used to halt puberty in gender-confused youth have been linked to thousands of adult deaths, government data show.

The Food & Drug Administration has recorded thousands of deaths associated with Lupron, a puberty-blocking drug that is routinely used to treat prostate cancer in men and endometriosis in women. Adverse complications related to its use include breast disorders, malignant neoplasms, and psychiatric and nervous disorders.

Lupron and other drugs in its class significantly alters the hormone levels in the body and has been documented to contribute to blood clots and other cardiovascular complications, as well as brittle bones and faulty joints.

Between 2004 and June 30 of this year, the FDA documented33,478 adverse reactionssuffered by patients who took Leuprolide Acetate (Lupron), which is used as a hormone blocker. More than 19,054 reactions were considered "serious," including 6,056 deaths.

The figure rises when factoring in the total number of adverse reactions logged by the FDA since 1984. In total, there have been 40,764 adverse reactions, 25,513 of those were considered "serious," among those were 6,370 deaths.

Lupron is being prescribed off-label for use in children who have been diagnosed with gender dysphoria despite the lack of formal FDA approval for that purpose. The drug is clinically approved for treatment of precocious puberty, a condition where children start their pubertal processes at an abnormally early age and the blocker is administered for a short time until the proper age.

"The first well-documented case report of a puberty blocker like Lupron (a similar medication called Triptorelin which has an identical mechanism of action) being used in a young patient with gender confusion was published out of Holland in 1998 where a pediatric endocrinologist, working together with a psychiatrist, decided to use the medication on a 13-year-old girl suffering from gender dysphoria,"Michael Laidlaw, a Rocklin, California-based endocrinologist, told The Christian Postin a previous interview.

Reports have emerged in recent years showing that the pediatric version of the drug comes with few warnings about long-term side effects and leads to lasting and severe health problems.

When injected into a physically healthy body, the drug interrupts a normally-functioning endocrine system, yielding hypogonadotropic hypogonadism, according to Laidlaw.

Its a serious condition that endocrinologists would normally diagnose and treat because it interferes with development, but in [gender dysphoria] cases theyre inducing this disease state, he said in aninterviewwith the National Catholic Register.

In 2017, the FDA said it was "conducting a specific review of nervous system and psychiatric events in association with the use of GnRH agonists, [a class of drugs] including Lupron, in pediatric patients, in response to questions from Kaiser Health News and Reveal from the Center for Investigative Reporting. The government agency was also reportedly reviewing seizures that stemmed from use of Lupron's pediatric version and other drugs in its class.

Transgender activists often promote such drugs as a "pause button" on life, giving young people additional time to decide whether to proceed to cross-sex hormones and surgical transition.

The therapeutic idea behind the use of Lupron for treatment of prostate cancer is that by inhibiting the flow of testosterone over the prostate and reducing it to a low, undetectable level, prostate cancer tissue is prevented from growing, Laidlaw told CPin a previousinterview about the drug's dangers.

Unlike prostate cancer, a disease where the drug at least serves the purpose of targeting the malignant masses on the organ, Laidlaw said he knows of no psychological condition that is treated by putting hormones out of alignment from their normal levels.

"Gender dysphoria is not an endocrine condition, but is a psychological one and should, therefore, be treated with proper psychological care. But it becomes an endocrine condition once you start using puberty blockers and giving cross-sex hormones to kids," Laidlaw stressed at the time.

According to the annual report of AbbVie, the company that produces Lupron, sales of the drug were approximately $669 million in 2017 in the United States alone.

England's lone gender clinic, the Tavistock Centre in London, has come under scrutiny in recent months in part because of intensifying public concern about puberty blockers.

Kirsty Entwistle, who until last October was a staff psychologist at the Gender Identity Development Service in Leeds, accused Tavistock clinicians in July of misleading young patients, saying they were making decisions that will have a major impact on children and young peoples bodies and lives ... without a robust evidence base" and said the facility had troubling internal practices.

Children and their families were being told that puberty-suppressing drugs used to transition youth were "fully reversible," when in fact the drugs' long-term effects remain unknown, she said, noting that an "unspoken rule" existed within the clinic that clinicians were never to inform families that their children were not transgender.

Visit link:
Drugs used as puberty blockers in youth linked to thousands of adult deaths, FDA shows - The Christian Post

Recommendation and review posted by Bethany Smith

AMA Research added a comprehensive research document of 200+ pages on Testosterone Replacement Therapy market with detailed insights on growth factors and strategies. The study segments key regions that includes North America, Europe, Asia-Pacific with country level break-up and provide volume* and value related cross segmented information by each country. Some of the important players from a wide list of coverage used under bottom-up approach are

Request a sample report @ https://www.advancemarketanalytics.com/sample-report/46424-global-testosterone-replacement-therapy-market

Testosterone is responsible for the development of male sexual characteristics and this hormone formed by the testicles. Insufficient production of testosterone causes erectile dysfunction. Testosterone Replacement Therapy (TRT) is generally termed as hormone therapy for men, designed to counteract the effects of reduced activity in the gonads or hypogonadism. Hypogonadism in men is clinical syndrome, which results in the failure of the testes to produce physiological levels of testosterone. Erectile dysfunction arises due to reduce testosterone production to overcome this testosterone replacement therapy is used to improve the problem.

Market Segmentation

by Type (Creams or Gels, Patches, Injections, Buccal Adhesives, Implants, Oral), Application (Hospitals, Clinics) Market Concentration Insights:

CR4, CR8 and HHI Index Analysis

Comparative Market Share Analysis (Y-o-Y)

Major Companies Market Position and Development Strategy

Emerging Players Heat Map Analysis

Check for Discount @ https://www.advancemarketanalytics.com/request-discount/46424-global-testosterone-replacement-therapy-market

Highlights of Influencing Trends: Increasing awareness about testosterone substitute therapy

Market Growth Drivers: Increasing prevalence of hypogonadism in adult men

The need for having an offspring amongst men

Restraints: High possibility of side effects related to testosterone replacement therapy

View Detailed Table of Content @ https://www.advancemarketanalytics.com/reports/46424-global-testosterone-replacement-therapy-market

Country level Break-up includes:

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Netherlands, Switzerland, Nordic, Others)

Asia-Pacific (Japan, China, Australia, India, Taiwan, South Korea, Middle East & Africa, Others)

On Special Request we do offer a dedicated and focus report on regional or by country level scope.

Get full copy of United States Testosterone Replacement Therapy Market Study @ USD 2000

And, Europe Testosterone Replacement Therapy Market Study @ USD 2500

Highlights from Table of Content (TOC):

1 Report Overview

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered

1.4 Market Analysis by Type

1.5 Market by Application

1.6 Study Objectives

1.7 Years Considered

2 Global Growth Trends

2.1 Global Testosterone Replacement Therapy Market Size

2.2 Testosterone Replacement Therapy Growth Trends by Regions

2.3 Industry Trends

3 Market Share by Key Players

3.1 Global Testosterone Replacement Therapy Market Size by Manufacturers

3.2 Global Testosterone Replacement Therapy Key Players Head office and Area Served

3.3 Key Players Product/Solution/Service

3.4 Enter barriers in Testosterone Replacement Therapy Market

3.5 Mergers, Acquisitions, Expansion Plans

4 Testosterone Replacement Therapy Market by Product

4.1 Global Testosterone Replacement Therapy Sales by Product

4.2 Global Testosterone Replacement Therapy Revenue by Product

4.3 Global Testosterone Replacement Therapy Price by Product

5 Testosterone Replacement Therapy Market by End User

5.1 Overview

5.2 Testosterone Replacement Therapy by End User

*Customized Section/Chapter wise Reports or Regional or Country wise Chapters are also available.

Buy this report @ https://www.advancemarketanalytics.com/buy-now?format=1&report=46424

Contact Us:

CRAIG FRANCIS (PR & Marketing Manager)

sales@advancemarketanalytics.com

Ph: +1 (206) 317 1218

More:
Testosterone Replacement Therapy Market: A Straight Overview of Growing Market & Future Trend by 2024 - Research Newscast

Recommendation and review posted by Bethany Smith

Eight Chromebooks in total will now receive software updates until June, 2025 rather than the original 2022 Auto Update Expiration date.

New Chromebooks come with a guarantee from Google of regular automatic updates for Chrome OS, but only for 6.5 years, and only for the underlying hardware platform. However, some Chromebooks are having their life extended by three years.

Purchasing a Chromebook may be cheaper than a laptop, but it will have an end-of-life date built in due to Google's Auto Update Expiration (AUE) 6.5 year time limit. Chromebooks will continue to work after their AUE, but won't get updates anymore or receive technical support. If you purchase a Chromebook the day it laucnhes then you get updates for 6.5 years, however, buying an older model means you may only get two or three years of updates.

What makes the situation more complicated is the fact Google attaches the AUE to the hardware platform rather than individual Chromebooks. So if a manufacturer uses Chromebook hardware that's a couple of years old in a new Chromebook, the AUE will be two years shorter. Google even advises manufacturers to always choose the newest platform so as to ensure the longest support.

As Chrome Unboxed reports, some Chromebooks now have a life extension courtesy of Google. There's eight in total, all except one are made by Lenovo. They include:

All eight Chromebooks were due to reach their AUE in June, 2022, but Google has extended the date so they will now continue to receive updates to June, 2025. The one caveat to continued support being that it relies on third-party component suppliers continuing to work with Google to support the devices for the next five years.

With the extended support in place, it makes these Chromebooks look a lot more attractive for anyone after a cheap, internet-focused laptop. For example, the Lenovo S330 is a 14-inch 1080p Chromebook with 4GB of RAM and 64GB of storage for just $269.

We can only hope that this limited extension turns into a more general extension of the AUE for all hardware platforms. If Google could extend support to 10 years, then all Chromebooks would be much better value for money, even if you are buying a model that's a couple of years old.

Read the original:
Google Extends the Life of Some Chromebooks by 3 Years - PCMag

Recommendation and review posted by Bethany Smith

USCGC Polar Star (WAGB-10) off McMurdo Sound near McMurdo Station, a United States Antarctic research center in 2018. US Air Force Photo

WASHINGTON, D.C. For the next several years, the Coast Guards only heavy icebreaker will lead the annual Antarctic resupply mission as the service develops its new class of icebreaker.

Called the McMurdo Breakout, the Coast Guards heavy icebreaker, USCGCPolar Star (WAGB-10), starts the journey to Antarctica every year at the end of October or early November. Once there, Polar Star breaks a channel through the sea ice so resupply ships can reach McMurdo Station, the National Science Foundations 164-acre research facility perched on the volcanic Ross Island in the Ross Sea.

In about a week, Polar Star is expected to leave drydock in Vallejo, Calif., return to its homeport Seattle for some final preparations, then in about a month, depart for the McMurdo Breakout, Lt. Cmdr. Stephen Brickey, a Coast Guard spokesperson told USNI News.

Typically, the breakout involves a fuel ship and a container ship a lifeline arriving once a year with the material needed to keep the station and field research operating for the year, said Scot Arnold, a senior advisor for the National Science Foundations Office of Polar Programs. Arnold was speaking recently at the American Society of Naval Engineers Arctic Day 2019 conference.

The Polar Star, it clears a channel for the two ships, Arnold said. You have to have the heavy icebreaker there to clear ice. It can be up to a 70-mile channel.

When all turbines on Polar Star are running, the icebreaker is an incredible machine, said Capt. Michael Davanzo, the Coast Guards chief of Cutter Forces, at the Arctic Day conference. The problem with Polar Star is its more than 40 years old and a challenge to keep operational.

In April, the Coast Guard awarded the $745.9 million contract to build its first of three planned Polar Security Cutters, the new class of heavy icebreaker to replace Polar Star. The Coast Guard expects delivery of the first PSC in 2024.

With Polar Star, our goal is to keep the cutter running through the delivery of the second PSC and to do that we have to do a service life extension which we think will take three to five years, Davanzo said. We have to try to do without missing a mission down to Antarctica.

Weather conditions in Antarctica and the expense of sending ships to the bottom of the world give the Coast Guard and the National Science Founding one chance at making the annual resupply mission. The McMurdo Breakout is timed for the height of the Antarctic summer at the end of December when high temperatures barely rise above freezing, but the sea ice can be broken, Arnold said.

The fuel tanker arrives with close to 10 million gallons of a special fuel mixture designed for use in Antarctica. The container ship arrives with bulk goods such as food, scientific equipment, vehicles and other material.

This year, and for several more, the container ship will also deliver the construction material used to build a massive new $355 million research facility that will fold the activities performed in 104 buildings into a condensed campus of six main structures, Arnold said.

Aerial view of McMurdo Station, which sits along the shoreline of Ross Island, a volcanic island in the Ross Sea. National Science Foundation photo.

Called the Antarctica Infrastructure Modernization for Science project, work is starting now and is expected to finish in 2026. Weather conditions limit the construction season to between October and April. Then the long, frigid Antarctic night sets in, halting outside work.

Antarcticas weather conditions also create a logistics challenge for such a large construction project. With supplies arriving once a year, in the middle of the construction season, Arnold said builders have to collect supplies a year ahead.

Were collecting materials now for the 20 season. Theyll be put on a ship and delivered to Antarctica in January, Arnold said.

Without the Coast Guards heavy ice breaker, though, these supplies cant reach McMurdo station, which would severely delay the carefully timed build. As sections of the new facility are built, work will migrate into the new structure. Crews will then demolish older structures, which in some cases are standing in the way of the projects final sections.

Once the materials arrive, the builders only have enough time to unload the ships and move most of the material to a storage field. When the construction season ends in April, the team will start sorting and prepping next years building supplies.

It gets off-loaded then dumped because we dont have the space to go through everything nor the manpower, so it all goes to a central receiving field, he said.

When finished, the new McMurdo station will save the National Science Foundation millions of dollars in operations and maintenance costs while also improving the living and working conditions for staff, with a relatively open and flexible floorplan to accommodate future research projects, Arnold said.

Its basically taking our old facilities, which have been around, in some cases since the fifties, from what really represents more of an expeditionary type construction, and bringing it into the future, for the next 50 years, Arnold said.

Related

Link:
McMurdo Station Expansion Relies on Coast Guard Heavy Icebreaker - USNI News - USNI News

Recommendation and review posted by Bethany Smith

Petasites Japonicus is an herbaceous perennial plant which is also known as Japanese sweet coltsfoot and Japanese butterbur. Petasites Japonicus belongs to asteraceae family, primarily found in Japan, China, Korea and Europe. Petasites Japonicus was introduced to Western Europe by Japanese immigrants. The stalk of petasites japonicus is known as fuki, which is a rich source of potassium, manganese, copper, calcium, and vitamin. Now a days petasites japonicus extract has be used for the prevention of migraine and the treatment of allergic rhinitis. Petasites japonicus extract has anti- inflammable properties which instantly reduces inflammation caused by arthritis or immune response.

Market Segmentation:

Browse more detail information about this report visit at at https://www.transparencymarketresearch.com/petasites-japonicus-extract-market.html

Petasites Japonicus extract market is segmented on the basis of type, end-user, application, and region. On the basis of type the market is segmented into petasites japonicus leaf extract and petasites japonicus root extract. The demand for petasites japonicus extract is increasing as it offers many anti-oxidant properties as well as is a rich source of flavonoid. On the basis of end-user the market is segmented into industrial and retail. The retail segment is further sub-segmented into supermarkets/hypermarkets, convenience stores and online stores. It is expected that online store will hold a relatively higher share in the petasites japonicus extract market compared to other distribution channels. On the basis of application the petasites japonicus extract market is segmented into cosmetic industry, and pharmaceutical industry. Pharmaceutical industry is expected to hold the major market share in the forecast period.

Market Regional Outlook:

Regional segment for the market of petasites japonicus extract is divided into five different regions: North America, APAC, Europe, Latin America and MEA. Among these regions Asia Pacific is expected to be the major contributor of petasites japonicus extract market globally and is expected to dominant the market in the forecaster period. In Asia Pacific region countries such as China and Japan holds the key market for petasites japonicus extract. In Europe region countries such as Italy and Spain holds the key market for petasites japonicus extract. In terms of revenue Europe is expected to be the second leading contributor of the petasites japonicus extract market in the forecast period.

Request For Custom Research At https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=26534&source=atm

Market Drivers:

Petasites Japonicus extract has been popular from ancient times and increasing awareness among the consumers about the health benefits associated with petasites japonicus extract is expected to drive the market in the near future. Petasites japonicus extract offers various health benefits such as it enables to reduce pain and swelling (inflammation), helps in the treatment of wounds, enables to reduce common cold, as petasites is an antihistamine element, therefore it helps to prevent allergic reactions, helps to reduce headaches and reduce fever and also helps to control the blood sugar level of the body which is expected to bolster the growth of the petasites japonicus extract market. The demand for anti-aging cream is further expected to boost the petasites japonicus as antioxidants present in the root extract helps in preventing free radical damage of the body. Petasites japonicus extract is also known to cure dehydration, potassium and magnesium deficiency along with calcium deficiency in pregnant women. Furthermore, it contains flavonoid which keeps the level of bad cholesterol low, these factors are also expected to drive the Petasites Japonicus extract market during the forecast period.

Market Key Players:

Some of the key players in petasites japonicus market are Swanson, Planetary Herbals, Solaray, Life Extension, Vitacost, Hawaii Pharm LLC, Piping Rock Health Products, Linpharma, Inc and Source Naturals among others.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications. The study is a source of reliable data on: Market segments and sub-segments Market trends and dynamics Supply and demand Market size Current trends/opportunities/challenges Competitive landscape Technological breakthroughs Value chain and stakeholder analysis The regional analysis covers: North America (U.S. and Canada) Latin America (Mexico, Brazil, Peru, Chile, and others) Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg) Eastern Europe (Poland and Russia) Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand) Middle East and Africa (GCC, Southern Africa, and North Africa) The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industrys value chain. A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period. Highlights of the report: A complete backdrop analysis, which includes an assessment of the parent market Important changes in market dynamics Market segmentation up to the second or third level Historical, current, and projected size of the market from the standpoint of both value and volume Reporting and evaluation of recent industry developments Market shares and strategies of key players Emerging niche segments and regional markets An objective assessment of the trajectory of the market Recommendations to companies for strengthening their foothold in the market Note:Although care has been taken to maintain the highest levels of accuracy in TMRs reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Request for TOC of This Report visit at https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=26534&source=atm

Read the rest here:
Petasites Japonicus Extract Market boosting the growth Worldwide: Market dynamics and trends, efficiencies Forecast 2022 - Space Market Research

Recommendation and review posted by Bethany Smith

Bank of Nova Scotia grew its stake in Sealed Air Corp (NYSE:SEE) by 7.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 128,998 shares of the industrial products companys stock after purchasing an additional 8,668 shares during the period. Bank of Nova Scotia owned about 0.08% of Sealed Air worth $5,519,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in SEE. LSV Asset Management purchased a new stake in Sealed Air in the 1st quarter worth approximately $50,283,000. APG Asset Management N.V. boosted its position in Sealed Air by 173.0% in the 2nd quarter. APG Asset Management N.V. now owns 829,152 shares of the industrial products companys stock worth $31,148,000 after purchasing an additional 525,381 shares in the last quarter. Renaissance Technologies LLC boosted its position in Sealed Air by 23.8% in the 2nd quarter. Renaissance Technologies LLC now owns 1,408,334 shares of the industrial products companys stock worth $60,249,000 after purchasing an additional 271,125 shares in the last quarter. AJO LP purchased a new stake in Sealed Air in the 1st quarter worth approximately $7,036,000. Finally, Cibc World Markets Corp boosted its position in Sealed Air by 287.5% in the 2nd quarter. Cibc World Markets Corp now owns 195,749 shares of the industrial products companys stock worth $8,374,000 after purchasing an additional 145,235 shares in the last quarter. Institutional investors and hedge funds own 96.58% of the companys stock.

NYSE SEE opened at $41.37 on Monday. The business has a fifty day moving average price of $41.56 and a 200 day moving average price of $43.47. Sealed Air Corp has a one year low of $30.22 and a one year high of $47.13. The company has a market cap of $6.33 billion, a P/E ratio of 16.55, a P/E/G ratio of 1.45 and a beta of 1.08.

Sealed Air (NYSE:SEE) last posted its quarterly earnings data on Friday, August 2nd. The industrial products company reported $0.80 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.64 by $0.16. Sealed Air had a negative return on equity of 121.14% and a net margin of 7.84%. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same period in the prior year, the company earned $0.64 EPS. The firms revenue was up .5% compared to the same quarter last year. On average, research analysts predict that Sealed Air Corp will post 2.78 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 20th. Investors of record on Friday, September 6th were paid a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 1.55%. The ex-dividend date of this dividend was Thursday, September 5th. Sealed Airs dividend payout ratio is currently 25.60%.

A number of brokerages have recently issued reports on SEE. Wells Fargo & Co increased their target price on Sealed Air from $42.00 to $43.00 and gave the company a market perform rating in a research report on Tuesday, August 6th. ValuEngine lowered Sealed Air from a hold rating to a sell rating in a research report on Wednesday, September 4th. KeyCorp reiterated a sell rating and set a $39.00 target price on shares of Sealed Air in a research report on Friday, August 2nd. Finally, Bank of America lowered Sealed Air from a buy rating to a neutral rating and set a $41.63 target price on the stock. in a research report on Friday, June 21st. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the stock. The stock has an average rating of Hold and a consensus target price of $42.69.

Sealed Air Profile

Sealed Air Corporation provides food safety and security, and product protection solutions worldwide. It operates in two segments, Food Care and Product Care. The Food Care segment offers integrated packaging materials and equipment solutions to provide food safety, shelf life extension, and total cost optimization for perishable food processors in the fresh red meat, smoked and processed meats, poultry, and dairy markets under the Cryovac, Cryovac Grip & Tear, Cryovac Darfresh, Cryovac Mirabella, Simple Steps, and Optidure brands.

See Also: Insider Trading

Receive News & Ratings for Sealed Air Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sealed Air and related companies with MarketBeat.com's FREE daily email newsletter.

See the original post here:
Sealed Air Corp (NYSE:SEE) Shares Acquired by Bank of Nova Scotia - TechNewsObserver

Recommendation and review posted by Bethany Smith

Poland is rolling out Biogensspinal muscular atrophy (SMA) therapy Spinraza (nusinersen) at a faster pace than any country that has approved it, Polish experts say.

Since the first injection in May 2019, about 400 of the 830 patients in Polands SMA registry have either started taking Spinraza or been put on a waiting list to obtain it, according to Kacper Rucinski, president of Warsaw-basedFundacja SMA. A commission of top neurologists is steadily adding patients to the list after determining that they qualify for National Health Service coverage of the treatment.

Longtime SMA expert Anna Lusakowska, a doctor at the Warsaw Medical University Neurology Clinic, predicted that Polish patients who want Spinraza will eventually get the medicine.

However, not all 830 will opt for it, said Rucinski, who along with Lusakowska spoke with SMA News Today by phone. Some patients with the muscle-wasting disease are receiving Roches risdiplam or Novartis branaplam in clinical trials. They would likely stay with their current treatments once those two medications are approved by the Health Ministry and covered by the national health insurance program.

Spinraza is very expensive; both risdiplam and branaplam also will be, upon approval. The U.S. retail price of Spinraza is $750,000 for the first year and $375,000 in subsequent years, although Poland, like all members of the European Union, negotiated its own price with Biogen.

Spinraza first became available in 2017 to a few dozen Polish patients under Biogens expanded-access program. In December 2018 18 months after Spinraza received European Union approval Poland authorized its National Health Service to pay for it.

Hospitals in three of Polands 16 regions spearheaded Spinraza treatment in 2017. Lusakowskas hospital, in the Masovia region which includes Warsaw joined them last year.

Not only did most of the regions outside Warsaw have no experience with Spinraza; they had never even treated SMA patients before, said Lusakowska, who started Polands SMA registry in 2010.

About 120 of Polands SMA patients live in the Warsaw area. As a result, the neurology programs at Warsaw Medical University and Childrens Memorial Health Institute in Warsaw became leaders in treating the disease decades ago.

After the national health insurance program began covering Spinraza, Lusakowskas neurology department decided to administer the medicine to as many people with SMA as possible. Thats led to long hours for staffers, but also has allowed Lusakowskas team to develop a level of expertise solid enough to share with inexperienced practitioners in other regions.

Patients with severe curvature of the spine are a special challenge, even if they have had previous surgery to correct their scoliosis, she said.Radiologists at Lusakowskas clinic use a computerized tomography (CT) scanner to administer injections to individuals with badly curved spines. The scanner shows the best locations for injecting those with scoliosis.

Four months after Polands first non-early-access injection, all regions are offering Spinraza, although it hasnt been easy, Lusakowska said. The surge in Spinraza patients since May has overwhelmed neurological clinics, which in addition to SMA deal with strokes, epilepsy and many other nerve-related conditions.

Lusakowska began her neurology career as an SMA specialist in the mid-1990s, just asscientists were discovering the cause of SMA defects in the SMN1 gene.She and other SMA specialists hoped researchers would develop a therapy quickly.

I worked with SMA patients for 30 years before a treatment came, Lusakowska said. Its really wonderful that I can finally do something for them.

The first Spinraza injection is emotional for patient, family and doctor alike, she said.

Usually the patient cries, the mother cries they have been waiting such a long time for this, she said.

Lusakowska said she can deal with the expressions of joy, even if they include tears. Its harder when the emotion is the anguish of patients calling to complain that they have had to wait such a long time for Spinraza but are still not receiving it, she said.

Like most countries, Poland prioritizes Spinrazas roll-out by age and disease severity. Children younger than 3 years old withSMA type 1 the worst form of the disease get top priority because research has shown they can benefit the most.

Adults with advanced stages of SMA are believed to gain less from treatment, though the main focus of Lusakowskas clinic is adults. She and her colleagues are administering Spinraza to 35 people in their 20s and older with different types of SMA, and expect to treat 70 eventually.

The 35 include seven type 1 patients. Six began taking Spinraza in Belgium under the expanded-access program, but returned to Poland after the National Health Service agreed to cover the treatment costs. The clinic also treats several children above the age of 3.

Lusakowska said Spinraza benefits all her SMA patients. Some improvements are obvious to doctors, while others are not but patients say it is helping them. Within a year, her clinic will have enough month-to-month, muscle-strength comparison data for a scientific assessment of Spinrazas effectiveness.

Some improvements have been amazing, Lusakowska said. That is the case, for example, with a 4-year-old Polish girl with SMA type 2 who began taking Spinraza in France when she was a few months old. Doctors had diagnosed her SMA in the womb after her older brother developed type 2. He also receives Spinraza.

Her brother is improving all the time with Spinraza, Lusakowska said. He is not walking, but he is much stronger. But his sister, who began receiving Spinraza when she was 3 months old, is walking, jumping, dancing shes a normal girl.

Another heartening sign is that, thanks to Spinraza, some patients who had been on detachable ventilation devices 16 hours a day have been able to reduce that to 10 hours a day.

Similarly, some patients say their voices are becoming much stronger as Spinraza strengthens their larynx muscles, Lusakowska said.

She praised the Health Ministry for deciding to cover all SMA patients who want Spinraza, rather than restricting it only to those in certain categories.

We dont have to turn anyone away, she said. We can tell all our patients that maybe not this month, but next month, we can treat you.

Hal Foster is a veteran journalist at the Los Angeles Times and other news organizations in the United States and Japan, and a longtime journalism professor.In addition to the LA Times, he worked at the Portland Oregonian and the Seattle Post-Intelligencer, was executive editor of Pacific Stars & Stripes in Tokyo, and wrote about the war in Ukraine for USA Today.He has a Ph.D. in journalism from the University of North Carolina, and has taught in the United States, Kazakhstan and Ukraine, where he was a Fulbright scholar.

Total Posts: 85

Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.

View post:
Nearly Half of Poland's SMA Patients on Track to Get Spinraza, Experts Say - SMA News Today

Recommendation and review posted by Bethany Smith

Eugene Gene Gulish, Michael P. Dansack, Jr. and John S. Szuch will be among the honorees at the Distinguished Alumni & Athletic Hall of Fame Banquet Thursday, Oct. 3 from 6-10 p.m. at St. Michaels Centre, 4001 Navarre Ave., Oregon. Eugene Gene Gulish was born June 10, 1937, in Curtice, where his parents had a restaurant and small farm. When he graduated in 1955 from Clay High School, he was the first in his family to do so. He attended the University of Michigan, planning to be a high school biology teacher, but he decided hed rather teach at a university. He earned a Masters Degree in Embryology and a Doctor of Medicine Degree from The Ohio State University. He did his internship and residency at LA County-USC Medical Center, and a four-year orthopedic residency followed. It was during this time that he decided to enter private practice. Gulish was drafted into the Army as a Major and was sent to Fort Polk, Louisiana. He was an orthopedic surgeon while there, and operated on many wounded soldiers from the Vietnam War. He received the Army Commendation Medal upon his discharge in 1971. He started a private practice in Sebastopol, California. About this time, arthroscopic surgery was introduced. He performed the first total knee replacement north of San Francisco and the second total hip replacement. Gulish moved to Paris, Tennessee, in 1994 because they were in desperate need of an orthopedic surgeon. At age 82, he was still practicing three days a week. All of his children work in healthcare one is an orthopedic surgeon, two are physicians assistants, one works with autistic children, and one teaches marriage and family therapy on the college level. Early in his career, Gulish realized how much he enjoyed medical mission work. He has traveled many times to a mission hospital in Kolo Ndoto, Tanzania. In 2010, he traveled to Haiti to assist earthquake victims. He traveled to Nigeria on a medical mission trip to Nigeria in June. Michael P. Dansack, Jr., graduated from Clay High School in 1978, and went on to the University of Toledo College of Engineering, graduating in 1982 cum laude with a Bachelor of Science in Industrial Engineering. He subsequently graduated from the Toledo College of Law in 1985. He is a partner at the law firm of Gallon, Takacs, Boissoneault & Shaffer. He participates on a bi-weekly basis on 13abcs Ask the Expert segment, providing answers to viewers legal questions during the noon newscast. Dansack served on Oregon City Council from 1983-89, serving as president from 1984-89. He earned the distinction of being the youngest person in Oregons history to be elected as mayor at the age of 29. He served as mayor from 1989-93. He has been an elected member of the Educational Service Center of Lake Erie West Governing Board from February 2010 to the present, serving two years as board president. His community service also includes serving on the Toledo-Lucas County Library Board, the Lucas County Mental Health Board, the Harbor Behavioral Health Care Board of Trustees, the St. Charles Mercy Hospital Advisory Board of Trustees, the Oregonian Club, the Oregon Plan Commission, the Oregon Growth Corporation and Bethany House. He participated in several volunteer activities, including coaching from 1978-1985 for the Oregon Recreation Department and coaching for the Anthony Wayne Recreation Department. He was an announcer for the Clay High School Fighting Eagle Marching Band from September 1978-November 1988. Dansack provided pro bono legal services in 2000 to the Clay High School Athletic Boosters, Inc., including the incorporation of a non-profit corporate entity and application for a 501(c)(3). He also offered his services to the Oregonian Club Charitable Fund for the same services. His services in 1997 to the Clay High School Stadium Renovation Fund, Ind., included the creation of a non-profit corporate entity. John S. Szuch graduated from Clay High School in 1966. He earned a Bachelor of Business Administration and an MBA from The University of Toledo. He completed the University of Michigan Graduate School of Banking and Financial Services Program and is a graduate of the Sheshunoff banking programs. Szuch was employed in various lending and management positions at Trustcorp, Toledo from September 1973 through June 1988. As senior vice president of Trustcorp, he was responsible for the operation of the Metropolitan Banking Division. He was a co-founder, chairman and chief executive officer of Capital Bank, N.A., a $1 billion organization which opened for business in August 1989. Capital Bank merged into Fifth Third Bancorp on March 9, 2001 with a total transaction value of approximately $250 million. Formerly chairman of Fifth Third Bank of Northwestern Ohio, a $3 billion subsidiary of Fifth Third Bancorp, he is currently an executive officer and member of the board of directors of Signature Bank, N.A., a $800 million regional bank headquartered in Toledo. Szuch is a member of St. Johns Jesuit High School Foundation Board, chairman of their Technology Center Fund Campaign and chairman of their Setting the Pace capital fund drive. He was an Ernst and Young Entrepreneur of the Year in 1996, and received the University of Toledo Pacemaker Award in 2005. Szuch currently serves on the Trustee Committee of the University of Toledo Foundation and as the chairman of the Toledo-Lucas County Port Authority. He is also a trustee and member of the Finance Committee of the Toledo Symphony Orchestra, and a trustee and chairman of the Toledo Museum of Art Finance Committee. He serves as a trustee of Second Harvest Community Services of Northwest Ohio and a trustee and finance chairman of St. Ursula Academy.

See the original post:
Three to be honored as Distinguished Clay High School Alumni - Press Publications Inc.

Recommendation and review posted by Bethany Smith

Dariel Norris and Gene Pollard are competing for Position 2 of the King County Hospital District No. 4. The district comprises the cities of Snoqualmie, North Bend and Carnation, as well as unincorporated and rural areas nearby.

Norris has a Bachelor of Science degree from the University of Washington and has the occupations of hospital registered nurse and small business owner. She has also served on the King County Parks Levy review board and the Snoqualmie Valley Community Network board.

Pollard has degrees from the University of California, Riverside and Occidental College. He also attended the Naval War College where he earned a diploma. Pollard is a retired foreign service officer, Navy commander, according to his candidate statement on the King County Auditors Office website.

Biggest health care problem facing Snoqualmie/the health care district?

Norris: I would say the ability to meet the specific health care needs of the local community. The 2016 Community Health Data Report identified the following issues for the Hospital district: access, cancer, heart and lung disease, mental health, smoking, substance abuse, diabetes, homelessness for adults and youth, all with serious health consequences.

Pollard: The major problem facing the district is the long-term indebtedness of $100 million, the greatest of any comparable hospital in the U.S. This didnt just happen overnight; it took years to accumulate. I attribute this to poor financial planning and incompetent policy making, especially by the hospital boards finance committee headed up by commissioners David Speikers and Dariel Norris. Committee meetings were briefly open to other commissioners and the public under former superintendent Tom Parker, who left a year ago to take a position with Mammoth Hospital in California. But now the committee has decided to again close its meetings, so financial decisions come to the board for rubber-stamping without dissenting opinion or transparent discussion.

How do we address this problem?

Norris: At present, the hospital district hasnt been able to reach out to the local community with supporting programs that aggressively address the above issues. Many who live in the district dont realize the hospital has clinics, physical therapy or an infusion program. Lab services as well as endoscopy and colonoscopies are available. We have an X-ray department with not only an Xx-ray machine but also MRI and CAT scan machines. In addition, we also have an infusion program. Even if your primary doctor isnt part of the Snoqualmie system, you can still have your test done close to home and have the results sent to your primary doctor. I believe the district needs to aggressively reach out to our local community, find ways to let them know what we have to offer. I would like to see programs such as nutrition classes from a dietitian or exercise classes from the physical therapy department. I would like the district to have support groups for those caring for family members with Alzheimers or dementia. I think day surgery and particularly orthopedics would be an asset for the community. Snoqualmie Valley Hospital has significant strengths. I sit on the quality committee. We get data that compares us with other local facilities. Based on the data we consistently do very well. If there is an issue, the staff addresses it immediately.

Pollard: Any organization $100 million in debt is in trouble by definition, especially where public money is involved. Whats needed is change change at the top in the finance committee, and in the position of the interim superintendent. The district needs to do a national search to identify a superintendent with prior success in hospital leadership, preferably including experience restoring financially-troubled hospitals. The district also needs greater transparency and accountability in district operations. For example, the proposal for a new hospital was pitched to the community on the basis that the old hospital would be sold for $30 million to the Snoqualmie Tribe and a new hospital would cost $38.6 million. That sounded reasonable, but then the district failed to demand payment when due. With $28.5 million still owed, the district discounted the sale price by half, thereby losing about $10 14 million. I voted against the discounting. Ive often been criticized for my No votes, but the fact is that if other commissioners had voted the way I have during my tenure, there would be no $100 million debt. Equally important to the success of this or any hospital is its communication with the public. The district is deficient. In fact, a local newspaper gave the hospital the grade of F in communicating with the public. Public information and advice on health issues have been missing, especially regarding preventative health. The public is uninformed about whats going at the hospital. They dont attend board meetings, held in the hospital basement, and there is essentially no media coverage. Importantly, the district needs to complete the Community Health Needs Assessment (CHNA) required by the Affordable Care Act and also by the IRS to justify the hospitals tax-exempt status. This is required every three years and must follow specific instructions. The districts 2016 CHNA was a quick and dirty copy of Overlake data and did not comply with the instructions. The 2019 CHNA is becoming overdue, which means the district will be out of compliance. An updated CHNA would assist the district in choosing and budgeting for health care priorities that would benefit the community.

In which direction do you foresee health care in the city/district moving?

Norris: Health care, in Snoqualmie and throughout the country, is struggling with payer models as well as a physician shortage which is growing daily. To meet the needs of Snoqualmie, we need to provide additional services. Services for the very young to the very old and everyone in between. The services need to be close to home and readily available.

Pollard: Because of the indebtedness, the district is now desperately seeking an affiliation, currently with Overlake Medical Center of Bellevue. Overlake is considering a short-term lease arrangement, perhaps five to seven years, which I dont consider viable. More importantly, I dont find Overlake to be a suitable partner. This is based on evaluations by national rating organizations, which dont list Overlake among the top six hospitals in the Puget Sound area. Its also based on my own experience as a patient at Overlake. The district has made many mistakes over the years (witness the debt). I feel that any decision to affiliate with Overlake, whereby this private hospital would take over all hospital operations, would be a historic mistake. It should be noted that Overlake would not bring one dime to the partnership, in contrast to the merger that occurred between Swedish Medical Center and Stevens Hospital in Edmunds. The Everett Herald reported that Swedish planned to invest as much as $90 million in that partnership over 10 years. In contrast, Snoqualmie would receive no funds from Overlake that might be used to help offset its long-term debt.

What are your budget priorities?

Norris: I was appointed to the finance committee six years ago. I was shocked to see some of the unnecessary extravagant expenditures. This is no longer the case. We have streamlined the executive staff. We have continued to budget with priorities in mind to reduce the debt while meeting the health care needs of the community. The present hospital was built with revenue bonds, not tax-backed dollars. The revenue bonds require a sizeable amount of cash on hand. Which we continue to maintain. The finance director suggested we invest those funds instead of letting them sit in the bank at a low interest rate. After a presentation, the chair of the finance committee, made a recommendation to invest those dollars. I believe this to be one of the most responsible choices and decisions the board of commissioners has made. We have also benchmarked as a way of discovering what is the best performance being achieved. This information can be used to identify gaps in an organizations processes in order to achieve a competitive advantage.

Pollard: My budget priority is to focus on austerity throughout the district. This includes looking at every position to make sure its really needed and properly compensated. I believe that some remain only because of the cronyism of prior administrations. A properly qualified new superintendent would be able to tighten things up and ensure the effective and economical operation of the district. Snoqualmie Valley Hospital and the Ridge Clinic belong to the taxpayers and residents of the district, not to hospital administrators or to the personal agendas of commissioners. Everyone associated with hospital governance and operations must remember they have a sacred trust to be good stewards of public funds.

Gene Pollard

Gene Pollard

View original post here:
Pollard and Norris in the race for Pos. 2 of the Public Hospital District 4 - Snoqualmie Valley Record

Recommendation and review posted by Bethany Smith

Dr. Mansour identifies two defining properties of stem cells: First, they can self-regenerate, meaning they divide and give rise to more regenerative cells of the same kind. Second, stem cells can mature or differentiate into specialized cells which carry out a specific function in the skin, muscle, or blood.

A major breakthrough in modern medicine revolves around the use of Umbilical Cord Stem cells. These powerful cells are injected into damaged tissues, ligaments, muscles and tendons, arthritic joints, or other tissues in an attempt to stimulate and accelerate healing.

Regenerative Medicine from Umbilical Cord Stem Cells in Macomb County

We were the first clinic in Michigan to offer umbilical cord stem cell injections as a holistic alternative to pain management and cell regeneration.

Dr. Mansour conducts monthly educational seminars and offers free one on one consultation, during which he reviews all imaging studies to determine if the patient is a candidate for stem cell therapy. For those who qualify, he offers a customized plan that is specific to each patient.

There is a wide range of conditions which may be treated with stem cells, including:

Joint Pain

Arthritis

Ligament Tears

Cartilage Tears

Meniscus Tears

Nerve Damage

Back Pain

And So Much More!

A Better Approach with Revolution Wellness

Are you suffering from constant discomfort, or diagnosed with a specific condition only to be told that medication or surgery are your only options? At Revolution Wellness, we believe otherwise. We use the innovative technology of stem cell therapy to treat discomfort and serious physical ailments.

Call our office today for more information about how we can get you on your way to living with less pain!

Read more:
Health Repair Damaged or Diseased Tissue with Stem Cell Injections 10:38 AM, Sep 28, 2019 - WXYZ

Recommendation and review posted by Bethany Smith

At 34, Noveel Pandya is an aspiring billionaire who has made it big right here in the UAE. Image Credit: Atiq Ur Rehman/Gulf News

Dubai: At 34, Noveel Pandya is a billionaire who has made it big right here in the UAE. While it would bealright to say he is more blessed than others his father, Narendra Pandya, ran an established business in the UAE before Noveel started Noveel is attempting to makea mark withhis own venture,Bioscience Clinic Middle East.

Senior Pandya runs a successful business House of Chemicals (HOC) - as a distributor of specialty and commodity chemicals for key suppliers especially in businesses such as oil drilling, refineries, gas plants, lubricant plants, water treatment for desalination plants and sewage treatment.

Pandya,Noveels father,also started another company BDH with an expertise in supply, installation, commissioning and maintenance of all laboratory equipment and furniture.

We are pretty much the turnkey laboratory projects expert, said Noveel, in an interview with Gulf News at his house in Emirates Hills.

But Noveels babyBioscience Clinic Middle East a center offering regenerative medicine and personalised autologous cell therapies brings him much pride and cheer. Premium services of the company include cryopreservation and expansion of cells used for anti-aging treatments, aesthetic and plastic surgery, wound care and for dermatological imperfections.

Starting from the bottom up

With a family-run business, it was perhaps a given for Noveel to become a businessman himself and run his fathers mantle.

But this was not achievedbefore he had to work his way up to the top.

In fact I started from bottom low. There was no way my father was going to have me take over peoples jobs in the company who had put in years of hard work. So there was a huge process of learning one that taught me humility and gratitude for the people who are part of our team, he said.

Noveels father came to work in the UAE in the early 70s. He said, From the stories I hear from him - there were many challenges and struggles he faced. In fact, lots of people who came with him to work in the UAE returned home.

It wasn't handed on a platter

Before jumping to the conclusion that he had it all easy,Noveel had to prove his capabilities just like any employee of the firm and had to work his way up the ladder.

There was no way my father was going to let me work above all those people who had put in so many years of service. From 2007 until 2011 it was all about learning and observation.

Take this: From the time Noveel completed his MBA in London in 2011 to join the family, he has helped the family business grow by a 100 per cent year on year.

Noveel said, BDH for example was making Dh35 million in 2007, but today, it is making over Dh140 million.

As for his own venture, there is massive potential for Bioscience Clinic Middle East as the stem cell venture business for the MENA region is tipped to be around $2 billion.

According to a report published in April 2019, the global stem cell market size is expected to reach $15.63 billion by 2025.

Today, we have little competition in the MENA region, so as you can see, there is a massive potential to grow.

Reverse-aging with stem cell therapy

Noveel said typically a client would reach out to a clinic to undergo a full scan and evaluation. A consultation with specialised doctors follows. Once the evaluation is done and the patient passes the test to become a candidate for the stem cell venture project, the doctor executes a plan to extract fat from the persons body.

This fat stores stem cells and we extract it from the fat. We have advanced technology in place to do the job for this. The stem cells derived are stored in vials and frozen, he explained.

The stem cells are multiplied to a couple of hundred million or sometimes a billion in order to produce the required volume.

Noveel said: When the stem cells are frozen they stop the ageing process of the cells. This means it effectively helps reverse-age a person. If someone at the age of 30 comes to us and asks us to freeze their cells. We do it. The person can always come back ten or 15 years later to rejuvenate their skin, hair or any part of their body.

"Just imagine at 45 or 50, this person wants to rejuvenate their skin. What we will do is inject their cells which were frozen when they were 30. When these cells are injected, they will leave the person with a skin looking as young as 30.

Stem cell therapy is said to be the most natural way to rejuvenate your skin, body and cells. The concept is called autologous which means it is your own cells which go into your body - not that of siblings or parents. Basically it is your own cells which are injected to the body and it is the most natural way to rejuvenate your body and skin.

How long does it take for the body to rejuvenate?

It depends on the body type, the persons lifestyle, food habits and more. This can take from a couple of weeks to a whole month. Remember, this is not an overnight fix. In fact treatments that come with overnight fixes can be very dangerous. Anything that has a drastic effect on your body is not good at all, explained Noveel.

We have seen fine lines or wrinkles disappearing in seven to 15 days after the cells were injected. The effect of the cell injected can last up to a year or over a year. But it all depends on the body type. Remember, your body can never reject your own cells it always accepts its cells.

Our clients are people from the age 18 and above. People who use alternative treatments come to us. I had a 63-year-old man come in from India saying they wanted their stem cells extracted.

Screening process

When a person comes there is a screening process that goes in. Upon successfully passing the screening process, other factors expel candidates like those who are typically heavy smokers or people with certain existing medical conditions.

If a client has a virus present in the body, that would drastically effect the quality of cells. If the quality of cells we get right in the beginning is poor the effect will not be desirable for them. Similarly, if the person is diagnosed with some STDs, certain terminal illness, we do not recommend them to store their cells.

Package cost

An initial package offered by Bioscience Clinic Middle East is close to Dh15,000 which includes a consultation, cell extraction, one year storage of stem cells and application. The application can be used anytime. One is not forced to use it immediately.

We are the only business in the region offering such services, Noveel claimed.

Business investment

Noveel said he invested 5 million euros in Bioscience Clinic Middle East.

This money went in for the facilitation of the lab, the treatment, and consultation, hiring skilled professionals and setting up class clean rooms for storing stem cells. Remember we are talking about a niche industry and a very niche product. The investment is for this.

Challenges as a millennial

There is a definite need to make an effort to be heard. Sometimes we are not taken seriously and that is the only challenge I see for myself today. But never give up. Keep dreaming and have the zest to grow. Patience is a virtue that we millennials need to build. Success does not come overnight. For example, my break-even did not happen for long. But I kept at my dreams and went after my goals. This is critical, Noveel said

Here is the original post:
Meet Noveel Pandya: Indian multi-millionaire whose stem cell venture project is the talk of town - Gulf News

Recommendation and review posted by Bethany Smith

When it comes to establishing a skincare routine, its not always straight forward. Long gone are the days of simply cleansing, toning and moisturising. We often hear words like peptides, retinol, vitamin C, acids and serums. But what do they all mean? But more importantly which product goes first?

One rule of thumb to guide you is to apply skincare products in order of their consistency, the thinnest first finishing with the thickest. But, its not just about knowing which order to apply them, its also important to know what products you need to use and how often to use them.

According to Dr Anita Sturnham, who specialises in dermatology, our skin has a 24-hour circadian rhythm, meaning that its anatomical and physiological needs change from AM to PM. In the day your skin needs protection from external factors like sunlight and pollution, in the evening its repairing itself. Which is why you need different products for different times of the day.

Its also important not to mix certain ingredients like exfoliating treatments and vitamin C together, otherwise they can counteract one and other.

Confused much?

To save you some serious head scratching, we have put together this clear, step by step guide on which order to apply your skincare products to take out the guess work for you.

AM routine:

As youve removed your makeup the night before, begin by using a light cleanser to clear the remnants of any skincare products or excess oils left on the skin. Your morning cleanser should be gentle, hydrating and non-abrasive.

Shop now Glossier Milky Jelly Cleanser, Glossier.com, 15

Shop now CeraVe SA Smoothing Cleanser, Feelunique.com, 12

Shop now L'Occitane Gel-To-Foam Cleanser, Debenhams.com, 19

Shop now La Roche-Posay Toleriane Dermo-Cleanser, Feelunique.com, 12.50

Next, use a water-based toner to help rebalance the skins PH levels and prepare your skin for your serum and moisturiser.

Shop now Dr Barbara Sturm Balancing Toner, Cultbeauty.co.uk, 45

Shop now Neal's Yard Rejuvenating Frankincense Toner, Feelunique.com, 20

Shop now Fresh Rose Deep Hydration Facial Toner, Cultbeauty.co.uk, 21

Shop now Caudale Beauty Elixir, Lookfantastic.com, 12

Follow by using an eye cream. Its important to use a separate eye cream because the skin around the eye area is a lot thinner and more sensitive than the rest of face. This is why its more prone to ageing over time, so using a hydrating eye cream rich in ingredients like hyaluronic acid and peptides help to boost collagen levels in the under eye area.

Shop now Vichy Minral 89 Eyes, Feelunique.com, 20

Shop now Clinique Moisture Surge Eye Concentrate, Lookfantastic.com, 27.50

Shop now Avne Soothing Eye Contour Cream, Lookfantastic.com, 9.50

Shop now Drunk Elephant C-Tango Multivitamin Eye Cream, Cultbeauty.co.uk, 54

Hyaluronic Acid is a key skincare ingredient which can be used by all skin types, according to Dr Sturnham: hyaluronic acid helps to provide structure to our cells and supports our skins hydration barriers. This extra hydration therefore helps to plump to the skin, minimising the appearance of fine lines.

In order to reap the maximum benefits, Dr Sturnham recommends applying hyaluronic acid in small layers throughout your morning and evening skincare routine, as well as using as a separate serum.

Shop now The Ordinary Hyaluronic Acid 2% + B5, Lookfantastic.com, 5.90

Shop now SkinCeuticals H.A. Intensifier, Lookfantastic.com, 85

Shop now Evolve Organic Beauty Hyaluronic Serum, Feelunique.com, 12

Shop now The Inkey List Hyaluronic Acid, Feelunique.com, 5.99

A serum is designed to penetrate the deeper dermal layers of your skin and nourish it with a variety of skin protective ingredients. Layering serums can also be effective to adapt your skincare routine to your specific skin needs.

Dr Sturnham recommends layering serums that have these key ingredients to promote healthy skin throughout the day:

Vitamin C - Vitamin C is an essential nutrient rich ingredient that should be used daily in your skincare routine. Our skin has built in receptors for Vitamin C says Dr Sturnham, which is why it is key to ensure we get our daily skincare fix of it. Vitamin C has many benefits such as improving skin tone, protecting the skin against pollution and UV damage, boosting cell repair and giving the skin a radiant look.

Panthenol (Vitamin B5) - Panthenol otherwise known as Vitamin B5 is an ingredient that helps to soften and soothe the skin by helping (repetition of skin) protect against irritation and water loss.

Ferulic Acid - Ferulic Acid is an antioxidant which helps to boost the effects of other antioxidants used in serums. It also helps to reduce signs of ageing like fine lines and wrinkles.

Shop now Decree Peptide Veil +, Cultbeauty.co.uk, 115

Shop now Paula's Choice C15 Super Booster, Lookfantastic.com, 46

Shop now Medik8 Hydr8 B5, Facethefuture.com, 32

Shop now The Ordinary Vitamin C Suspension 23% + HA Spheres 2%, Cultbeauty.co.uk, 4.90

Once you have applied your serum and given it time to absorb into the skin, it is then time to apply a moisturiser. This helps to hydrate your skin throughout the day and creates a smooth base for makeup. Dr Sturnham recommends non pore-clogging ingredients like safflower, apricot kernel and squalene.

Shop now Kate Somerville Goat Milk, Cultbeauty.co.uk, 55

Shop now Clinique Dramatically Different Hydrating Jelly, Feelunique.com, 31

Shop now Glossier Priming Moisturiser, Glossier.com, 18

Finish by using an SPF (Sun Protection Factor) to protect your skin against UV damage. UV damage causes signs of premature ageing such as wrinkling and pigmentation. Experts recommend using an SPF30 or higher on your face to deliver optimum UV protection.

Shop now REN Clean Screen Mineral SPF 30, Lookfantastic.com, 30

Shop now Kiehl's Ultra Light Daily UV Defense, Feelunique.com, 28

Shop now Vichy Ideal Soleil Mattifying Face Fluid Dry Touch SPF30, Feelunique.com. 16.50

Shop now SkinCeuticals Ultra Facial Defense SPF50+, Lookfantastic.com, 37

PM routine

For your evening cleanser use something with more active ingredients that has an exfoliation to it and that is deep pore cleansing. If you are wearing makeup and SPF during the day, we recommend double cleansing: using a balm or oil based cleanser first to breakdown the makeup and excess oil and following with a gentle, hydrating gel cleanser.

Shop now Emma Hardie Amazing Face Moringa Cleansing Balm, Lookfantastic.com, 47

Shop now The Body Shop Oils of Life Cleansing Oil-in-Gel, Thebodyshop.com, 12

Shop now Decree Deep Cleanse, Cultbeauty.co.uk, 55

Shop now DHC Deep Cleansing Oil, Feelunique.com, 11

Once again follow with a toner to balance your skins PH levels and prep your skin for your serum and moisturiser. You can also opt to use an acid toner two to three times a week depending on your skin type. Look for ingredients like glycolic acid, lactic acid and mandelic acid which will exfoliate the skin and even texture.

Shop now Dr Dennis Gross Alpha Beta Ultra Gentle Daily Peel, Lookfantastic.com, 87

Shop now Pixi Glow Tonic, Lookfantastic.com, 18

Shop now Nip & Fab Glycolic Fix Daily Cleansing Pads, Lookfantastic.com, 12.95

Shop now Paula's Choice 2% BHA Liquid Exfoliant, Lookfantastic.com, 28

If you are really invested in fighting signs of ageing and those pesky fine lines, retinol is the way to go. Otherwise known as vitamin A, retinol is a rich ingredient which helps to fight signs of ageing at a deep cellular level. It helps to promote the production of collagen and elastin, reduce pore congestion, regulate the production of sebum and work against inflammation.

There are many options for retinol on the market, but Dr Sternham recommends using retinol into your skincare routine in the form of a serum. Look for words like: granactive Retinoid or hydroxypinacolone retinoate which are less harsh on the skin.

Use it in small doses every night after cleansing and toning before applying your moisturiser and built up gradually. Make sure that you always use an SPF in your morning routine, as retinol will make your skin more photosensitive.

Shop now Medik8 Crystal Retinal 1, Facethefuture.com, 39

Shop now Elizabeth Arden Retinol Ceramide Capsules, Lookfantastic.com, 42

Shop now Drunk Elephant A-Passioni Retinol Cream, Cultbeauty.co.uk, 62

Shop now Disciple Dreamy Skin, Cultbeauty.co.uk, 35

Like your AM routine, follow up with an eye cream to the orbital bone area. We recommend saving yourself some money and opting for the same one morning and night.

Add a serum to your PM skincare routine like you would before a moisturiser in the day. Dr Sturnham advises to look for ingredients that support your skins physiological needs at night. Pay attention to how your skin is feeling, is your skin dry? Is it showing signs of pigmentation? Is your skin feeling congested? Look for serums that will address the particular needs of your skin and that ideally have a variety of skin benefiting ingredients. Dr Sturnham recommends ingredients like alpha arbutin, hyaluronic acid and plant-based stem cells.

Shop now Kate Somerville KX Active Concentrates Ceramides & Omegas, Spacenk.com, 84

Shop now Bybi Supercharge Serum, Feelunique.com, 32

Shop now The Ordinary Alpha Arbutin 2& + HA, Cultbeauty.co.uk, 7

Shop now Glossier Super Bounce, Glossier.com, 24

For your evening moisturiser use one with a slightly richer, thicker consistency than you would during the day to hydrate dehydrated skin.

Shop now Trilogy Replenishing Night Cream, Lookfantastic.com, 32.50

Shop now Herbivore Moon Fruit Night Treatment, Cultbeauty.co.uk, 48

Shop now CeraVe Moisturising Lotion, Lookfantastic.com, 9

Always Remember

-Avoid using exfoliating or foaming cleansers followed by alcohol-based toners, as this will dry out skin, making it prone to sensitivity.

-Take your time to apply each product, allow each layer to absorb into the skin before applying the next one.

-Use your treatment products in order of their consistency from lightest to thickness.

-Avoid mixing water-based and oil-based products in your same skincare regime.

-Keep your cleansing routine simple on a daily basis and reserve the more intensive exfoliation routine for once a week.

-Avoid using intensive exfoliators with Vitamin C.

Follow Emily on Instagram.

Originally posted here:
This is the correct order to apply your skincare products - cosmopolitan.com

Recommendation and review posted by Bethany Smith

Scroll To See More Images

Its safe to say that we are in a total German state of mind lately. And now that Oktoberfest is here, we are more than appreciative of the delicious international fare the season always brings. However, wed be foolish not to reflect on the awesomeness that is German beauty brands this month, especially since it seems to be having a major moment in 2019.

And while you may be trying to picture just how G-Beauty could ever dethrone the beauty behemoth that is K-Beauty, Martina Joseph, CEO of German brand Dr. Hauschka USA, explains that the German beauty scene is here to stay, especially since it has a strong emphasis on high-quality products and standards. Germany has a brilliant reputation for quality products and quality standards, says Joseph. The consumer is recognizing the value proposition of clean ingredients, and are seeking clean, sustainable, and responsible products.

And clean beauty factor aside, theres no denying that G-beauty is also popular due to its kind international appeal. Besides, we all know how popular French girl beauty still is to this day. To help you say hallo to the best German beauty brands, we rounded up nine skincare and makeup companies worth keeping on your radar. From drugstore-favorites to luxurious brands worth investing in, check out our top brand picks just in time for Oktoberfest below.

Dr. Hauschka may have an impressive roster of celebrity fans (including starlets like Anne Hathaway and Julia Roberts) to brag about, but its definitely for good reason, as this German skin-care brand utilizes natural ingredients to help improve the performance of your skin.

And aside from the cleansing, moisturizing, and nighttime needs the brand offers, its worth mentioning that Dr. Hauschkas toning products are equally exceptional. Dr. Hauschkas original facial toner, for example, is nothing short of a skin-care superstar, as it utilizes a potent blend of anthyllis and witch hazel extracts to gently clarify the skin.

$37 at Dermstore

Created by German dermatologist Dr. Tim Golueke, this luxurious line of anti-aging products has already found some firm footing in the states, as its currently sold at retailers like Bergdorf Goodman. But, dont let its hefty price tag fool you into thinking its just another cash grab, as this revolutionary brand utilizes unique ingredient Royal Fern (an extremely moisturizing evergreen plant thats also resistant to environmental influences) to combat skin aging on all levels.

The brands anti-aging anti-aging serum definitely uses a special Royal Fern Complex (plus hyaluronic acid and vitamin C from Acerola cherry) to protect the skin against genetic and environmental stress, making it a must for those who are looking to add an anti-aging alternative to retinol to their routine.

$295 at Violet Grey

This German skin-care brand is definitely a clean beauty enthusiasts dream, as each product contains minimally processed ingredients that dont contain preservatives, solvents, and surfactants. And while we are very impressed by Less amazing line of hairbrushes, theres no denying that the brands skin-care essentials are a must-see.

The Less Face Oil for Dry Skin, is one of the products we cant stop talking about, as it utilizes a blend of avocado, jojoba, and apricot oils for supple and moisturized skin.

$72 at Less

Seoul isnt the only authority on sheet masks now that this German skin-care brand has entered the fold, as it also delivers budget-friendly products that address all your skin woes. And sheet masks aside, Magicstripes has also unveiled some eye-raising products that have garnered media here in the United States. The brands eyelid lifting strips, for example, have been featured in outlets like Allure, making it something to see for yourself, should you be curious.

However, if sheet masks are practically your main squeeze, you really cant go wrong with this hyaluronic acid-infused product, as it leaves your skin feeling oh-so-hydrated in a matter of minutes.

$15.52 at MagicStripes

Combining revolutionary science with biological wisdom, this line of products was developed by German-born professor Augustinus Bader, who is globally recognized as one of the leading voices in regenerative medicine. And what makes this line of products unique is the innovative science behind it, as professor Bader studied how to perfect the skins healing process for up to 30 years. This same research ultimately led him to discover how to unlock the signals that trigger ones own stem cells.

Professor Bader initially applied his research to develop a special wound gel for severe burn victims. However, since the gel delivered remarkable results, it then inspired a full line of skin and body products to support the skins natural healing process. The anti-aging Augustinus Bader Body Cream is definitely one of the major highlights of this skin-care collection, as it drenches dehydrated skin in essential moisture.

$165 at Augustinus Bader

Hailing all the way from Frankfurt, this German beauty brand boasts an impressive line of high-quality brushes, palettes, lipsticks, and foundation products. However, you dont have to be based in Germany to score ZOEVA products, as the brands Authentik Skin Foundation is set to debut at Ulta later this month.

And unlike some drying foundations on this market, expect this rosehip oil-infused product to leave your skin feeling silky smooth upon application.

$28 at Ulta

NIVEA surprisingly has some strong German roots, as the brand was founded in 1882 by German physicist Paul Carl Beiserdorf. And while NIVEA products are definitely found abroad, youll love to know that they are pretty easy to find here in the states as well.

Drugstores like CVS and Walgreens, for example, actively carry Nivea products, making them an absolute must if you are looking to give your skin the TLC it deserves.But, if you are a newbie to the brand, we strongly recommend investing in the brands highly moisturizing cucumber body wash.

$6.49 at CVS

Founded by German aesthetics doctor, this sophisticated line of skin-care products (think creams, serums, and facial scrubs) has gained quite the celebrity fanbase. However, starpower isnt the only thing thats driving Dr. Barbara Sturms popularity onward and upward, as its innovative ingredient science is also worth buzzing about.

Apart of that science includes focusing on utilizing unique and powerful ingredients, as the brands full skincare range utilizes Purslane, an anti-aging powerhouse that helps calm down inflammation. If you are extra curious about adding Purslane to your routine, trust that Dr. Sturms new Skin Food supplement definitely uses this superstar ingredient (plus other skin-boosting antioxidants!) to help rehabilitate and protect your complexion.

$95 at Sephora

This affordable beauty brand also has some German roots, as its earliest origins stem back to 2004, when it was founded by Christina Oster-Daum. Flashforward to 2019, and its safe to say that Catrice has become nothing short of a global sensation, as its line of affordable makeup products can easily be found at American beauty retailers like Ulta.

Catrices HD Liquid Coverage Foundation surely is a product to consider if you are looking for affordable foundations, as it retails for just $10.99, and delivers long-lasting coverage.

$10.99 at Ulta

Our mission at STYLECASTER is to bring style to the people, and we only feature products we think youll love as much as we do. Please note that if you purchase something by clicking on a link within this story, we may receive a small commission of the sale.

Read more here:
German Beauty Brands to Try This Oktoberfest and Beyond - STYLECASTER

Recommendation and review posted by Bethany Smith

KEY POINTS

Although graft-versus-host disease is a leading cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation, involvement of the central nervous system in this disease is uncommon.

In patients with a previous hematopoietic stem cell transplantation presenting with neurologic manifestations, central nervous system graft-versus-host disease should be on the differential diagnosis.

Diagnosis of central nervous system graft-versus-host disease relies on exclusion of other infectious, autoimmune, vascular, drug-related and paraneoplastic processes, along with compatible imaging and histopathologic findings.

The primary treatment of central nervous system graft-versus-host disease is immunosuppression with high-dose corticosteroids.

A 68-year-old man presented to the emergency department with a 1-week history of sudden-onset myoclonus of his right leg. His medical history included allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome performed 742 days earlier, type 2 diabetes mellitus, hypertension and dyslipidemia. The patient had undergone a 9/10 unrelated human leukocyte antigen (HLA) donor transplantation, and after transplantation, his myelodysplastic syndrome was in complete remission and he had complete donor engraftment. On presentation, he was receiving methotrexate (10 mg by mouth weekly) for large granular lymphocytosis and acyclovir (400 mg by mouth twice daily) for herpes simplex virus prophylaxis. A detailed neurologic examination on presentation showed a right-sided pyramidal distribution of weakness and a stimulus-sensitive, spontaneous positive myoclonus, present in the right leg more than the arm, and absent in the face. Deep tendon reflexes were brisk on the right side.

Given this patients history of hematopoietic stem cell transplantation and relative immunosuppression with methotrexate, the differential diagnosis was broad and included central nervous system infections, central nervous system relapse of his primary malignancy, metabolic derangements, paraneoplastic process, microangiopathy, central nervous system vasculitis, toxicity related to immunosuppressive agents, and central nervous system graft-versus-host disease. On further history, it was noted that he received a reduced intensity conditioning transplantation with fludarabine, busulfan and total body irradiation of 200 Gy. His graft-versus-host disease prophylaxis was with anti-thymocyte globulin, and posttransplantation cyclophosphamide and cyclosporine.1

The patient was admitted to the internal medicine service, and neurology was consulted, given his neurologic findings. Magnetic resonance imaging (MRI) of the brain showed multiple scattered T2-weighted fluid-attenuated inversion recovery hyperintense, non-enhancing, mildly expansile, cortical and subcortical lesions in both cerebral hemispheres, with no associated restricted diffusion (Figure 1AD).

Axial magnetic resonance imaging of the brain in a 68-year-old man with myoclonus after allogeneic hematopoietic stem cell transplantation. Pretreatment (A) T2-weighted fluid-attenuated inversion recovery (FLAIR), (B) T1-weighted postgadolinium, (C) diffusion-weighted and (D) apparent diffusion coefficient mapping images showing multiple scattered cortical and subcortical non-enhancing T2 and FLAIR hyperintense lesions (arrowheads) throughout the supratentorial brain. The lesions did not show restricted diffusion by diffusion-weighted imaging and apparent diffusion coefficient mapping. Posttreatment with corticosteroids, (E) T2-weighted FLAIR, (F) T1-weighted postgadolinium, (G) diffusion-weighted and (H) apparent diffusion coefficient mapping images show resolution of lesions.

Over the following days, the patient had a rapid neurologic deterioration. He became nonverbal, and his only preserved motor function was smooth pursuit eye movements. Given this rapid progressive encephalopathy, the patient was treated empirically for viral encephalitis with acyclovir (800 mg intravenously every 8 hours). Despite this treatment, the patients clinical condition did not improve. Lumbar puncture showed a protein level of 0.53 (normal 0.20.45) g/L, a glucose level of 3.7 (normal 2.54.5) mmol/L and no pleocytosis. Microbiological and molecular analysis did not show any evidence of causative infectious pathogens; the analysis included an extensive panel of bacterial, viral (EpsteinBarr virus, cytomegalovirus, polyomavirus, varicella zoster, herpes simplex, human herpesvirus 6, rubella, measles, West Nile virus and arbovirus), parasitic (toxoplasmosis), prion (CreutzfeldtJakob disease) and fungal (Cryptococcus) infections. Electroencephalography showed diffuse slow wave activity corresponding to nonspecific encephalopathy but did not show any epileptogenic focus. There was no evidence of malignant cells on cerebrospinal fluid cytopathology and flow cytometry. A vasculitis panel including cytoplasmic antineutrophil cytoplasmic antibodies (c-ANCA), perinuclear ANCA (p-ANCA), antinuclear antibodies, anti-double stranded DNA, C3, and C4 was negative. Testing for antibodies for paraneoplastic syndrome was negative. Methotrexate-induced leukoencephalopathy, classically seen in patients receiving high-dose methotrexate, especially intrathecally, was included in the differential diagnosis. However, the patients MRI findings were inconsistent owing to sparing of the centrum semiovale, as well as a lack of restricted diffusion.2 Furthermore, his symptoms persisted despite discontinuation of methotrexate.

Given worsening of the patients clinical condition and radiographic findings despite 10 days of treatment with intravenous acyclovir, a brain biopsy of the left frontal parietal cortical lesion involving both grey and white matter was performed. This showed perivascular lymphocytic infiltrate (Figure 2A). Luxol fast blue stains showed the absence of demyelination (Figure 2B). There was evidence of microglial activation involving the neuropil and perivascular spaces, highlighted by CD163 immunostains (Figure 2C). A sparse CD3 positive T lymphocyte perivascular infiltrate was present, without direct infiltration of the vessel wall (Figure 2D). There were no CD20 positive B lymphocytes. The pathologic findings of perivascular infiltrate were consistent with literature reports of central nervous system graft-versus-host disease. Investigations looking for other sites of involvement including liver enzymes, cutaneous examination and endoscopy, although not exhaustive, did not show graft-versus-host disease of other organs.

Histopathologic images of the patients frontal cortex biopsy. (A) Hematoxylin and eosin staining showing sparse perivascular lymphocytic infiltrate in the white matter (arrowheads). (B) Luxol fast blue staining showing the absence of demyelination. (C) Perivascular activated microglia as shown by CD163 staining (arrowheads). (D) T lymphocytes infiltrating perivascular spaces (black arrowhead) and the neuropil (green arrowhead) as shown by CD3 staining. Scale bar = 200 m.

Even with this extensive workup, the patients diagnosis was unclear. It was imperative that infectious causes were considered and ruled out, which we had done. Given the patients clinical deterioration, a presumptive diagnosis of central nervous system graft-versus-host disease was made, and an empirical course of corticosteroid pulse was started (methylprednisolone 150 mg/d intravenously). Clinical improvement was rapid, and by day 3 of corticosteroid therapy, the patient was able to move his limbs and vocalize. He continued to improve and was ambulatory within 2 weeks of treatment. Repeat MRI showed resolution of many of the lesions (Figure 1EH). The patients dosage was subsequently tapered, and he was transitioned to maintenance prednisone (60 mg/d by mouth) and azathioprine (75 mg/d by mouth).

Unfortunately, recurrent infections developed while the patient was receiving immunosuppressive treatment. Three months later, as his prednisone was tapered, he again had a flare of neurologic symptoms, and MRI showed worsening of the lesions. The patients goals of care were changed to comfort measures, and he died 927 days after the transplantation and around 195 days after onset of the central nervous system symptoms.

Allogeneic hematopoietic stem cell transplantation is a life-saving treatment for many hematologic diseases. Graft-versus-host disease is a leading cause of morbidity and mortality after allogenic hematopoietic stem cell transplantation.3 Between 30% and 50% of patients will develop graft-versus-host disease, whereby the donated tissue (the graft) recognizes the recipient (the host) as foreign and mounts a T cellmediated immune response.4 The clinical manifestations vary, as multiple organs can be affected.

Classification of graft-versus-host disease has traditionally been divided into acute and chronic, depending on the onset of symptoms within or beyond 100 days, respectively. However, recent criteria consider overlap syndromes with increased emphasis on clinical features rather than timing of symptom onset alone.5,6 Central nervous system graft-versus-host disease is a rare but emerging entity after allogeneic hematopoietic stem cell transplantation, probably in part because the number of hematopoietic stem cell transplantations has risen.79

Although chronic graft-versus-host disease can affect any organ, the skin, gastrointestinal tract, liver, joints, fascia and lungs are most frequently affected. Signs and symptoms of graft-versus-host disease relate to the organs of involvement, including maculopapular rash, hyperbilirubinemia with jaundice, and abdominal pain with either nausea and vomiting or diarrhea.4 With such broad-ranging clinical features, diagnosis relies on the assessment of target organs by means of clinical, laboratory and pathological findings. Important risk factors include compatibility of recipient and donor, including degree of HLA mismatch, sex of donor and recipient, use of peripheral-blood stem cell grafts and the conditioning regimen used. Criteria from the National Institutes of Health (NIH) help in defining and stratifying chronic graft-versus-host disease.10 Because of the rarity of cases, central nervous system graft-versus-host disease is not defined in the NIH criteria.

Neurologic involvement (first documented nearly 3 decades ago11) is rare, and graft-versus-host disease afflicting both the central and peripheral nervous system has been described in the literature.79 Symptoms involving the central nervous system are often nonspecific and can include headaches, altered mental status, seizures and paresis.

In a recent case report and review, Ruggiu and colleagues reported a total of 39 presumed cases of central nervous system graft-versus-host disease, with a median patient age of 35 (range 0.6768) years and a median duration of symptomatic presentation of 385 (range 77320) days after transplant.8 In this case series, which is limited by a lack of histopathology in more than half of the patients, those presenting with central nervous system disease without other chronic features of graft-versus-host disease presented earlier and in most cases had a history of acute graft-versus-host disease.8

Our patient did not present with evidence of extracentral nervous system graft-versus-host disease. This may be owing to the newer conditioning regimen he was given, immunosuppression, or other underlying medical diagnoses and comorbidities. Our current lack of understanding of the clinical course of patients with central nervous system graft-versus-host disease highlights the importance of further research into identifying risk factors, developing better diagnostic tools and finding new strategies for prevention.

The diagnosis of central nervous system graft-versus-host disease is complicated by conflicting differential diagnoses that can be challenging to exclude, such as infection, drug and radiation toxicity, and primary disease metastasis. As such, a combination of microbiologic and laboratory studies, and radiographic and histopathologic findings are required for the workup.

Given these diagnostic challenges, the 2009 Consensus Conference on Clinical Practice in chronic graft-versus-host disease defined the neurologic manifestations of the disease.5 This definition included the following criteria: 1) occurrence with chronic graft-versus-host disease affecting other organs, 2) neurologic signs of central nervous system involvement without other explanation, 3) corresponding MRI brain abnormality, 4) abnormal cerebrospinal fluid findings, 5) brain biopsy or postmortem examination confirming graft-versus-host disease and 6) response to immunosuppressive therapy.5 Criteria 1 and 2 are considered mandatory requirements in the diagnosis of central nervous system graft-versus-host disease, whereas criteria 36 are facultative requirements. A definitive diagnosis can be made when all 6 criteria are met, and a possible diagnosis can be made when both mandatory criteria and at least 2 facultative requirements are met.

Our patient met all the criteria according to this consensus definition except the first (occurrence with chronic graft-versus-host disease affecting other organs). Interestingly, the case series by Ruggiu and colleagues showed that 28% of patients did not have extracentral nervous system features of chronic graft-versus-host disease, although most of these patients did have a history of extracentral nervous system acute graft-versus-host disease.8

Despite immunosuppressive treatment, central nervous system graft-versus-host disease portends a poor prognosis. Prior case series show that even though 70% of patients who received treatment with corticosteroids showed at least a partial response, only 18% of patients were alive at last follow-up.8

This case highlights the importance of the late central nervous system complications of hematopoietic stem cell transplantation, the challenges with diagnosis and the role of timely immunosuppressive therapy. Though concepts regarding central nervous system graft-versus-host disease continue to evolve, it is important to keep as a differential diagnosis in patients with noninfectious neurologic complications who have undergone hematopoietic stem cell transplantation.

The authors acknowledge the contributions of Russell Yanofsky, Sunu Cyriac, David G. Munoz and Auro Viswabandya.

Competing interests: None declared.

This article has been peer reviewed.

The authors have obtained patient consent.

Contributors: The authors all contributed substantially to the conception of this work, including acquisition, analysis and interpretation of raw patient data in the form of clinical examination findings or laboratory investigations on the patient. All authors were substantially involved in drafting and editing the work, including substantial contributions in their respective areas of expertise and in review of the contributions of the other authors. All authors give their final approval of the version to be published and agree to be accountable for all aspects of this work.

The rest is here:
Central nervous system graft-versus-host disease in a 68-year-old man presenting with myoclonus - CMAJ

Recommendation and review posted by Bethany Smith